UNITED STATES

0000950156-13-000066.txt : 20130814 0000950156-13-000066.hdr.sgml : 20130814 20130814130653 ACCESSION NUMBER: 0000950156-13-000066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130814 DATE AS OF CHANGE: 20130814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IGI LABORATORIES, INC CENTRAL INDEX KEY: 0000352998 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 010355758 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08568 FILM NUMBER: 131036532 BUSINESS ADDRESS: STREET 1: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 BUSINESS PHONE: 6096971441 MAIL ADDRESS: STREET 1: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 FORMER COMPANY: FORMER CONFORMED NAME: IGI INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGENETICS INC DATE OF NAME CHANGE: 19870814 10-Q 1 d901500_igi10q.htm BODY OF FORM 10-Q UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)


þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013


¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________________ to_______________________

Commission File Number 001-08568

IGI Laboratories, Inc.

(Exact name of registrant as specified in its charter)


Delaware	01-0355758
(State or other Jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

105 Lincoln Avenue Buena, New Jersey	08310
(Address of Principal Executive Offices)	(Zip Code)

(856) 697-1441

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No þ

The number of shares outstanding of the issuer's common stock is 43,251,415 shares as of August 2, 2013.

PART I

FINANCIAL INFORMATION

ITEM 1.

Financial Statements.

IGI LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share information)

(Unaudited)


	Three months ended June 30,		Six months ended June 30,
	2013	2012	2013	2012

Revenues:
Product sales, net	$ 3,706	$ 1,861	$ 7,174	$ 3,371
Research and development income	109	564	268	872
Licensing, royalty and other income	5	12	62	26
Total revenues	3,820	2,437	7,504	4,269

Cost and expenses:
Cost of sales	2,673	1,683	5,248	3,049
Selling, general and administrative expenses	706	615	1,386	1,273
Product development and research expenses	805	644	1,463	1,116
Total costs and expenses	4,184	2,942	8,097	5,438
Operating loss	(364)	(505)	(593)	(1,169)
Interest expense and other, net	(39)	(83)	(67)	(154)

Net loss	$ (403)	$ (588)	$ (660)	$ (1,323)

Basic and diluted loss per share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.03)

Weighted Average of Common Stock and Common Stock Equivalents Outstanding
Basic and diluted	43,206,016	39,522,868	43,070,335	39,511,745

The accompanying notes are an integral part of the condensed consolidated financial statements.

IGI LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share information)


	June 30, 2013		December 31, 2012*
ASSETS
Current assets:
Cash and cash equivalents	$	1,313	$	2,536
Accounts receivable, net		2,602		1,577
Inventories		2,104		1,773
Prepaid expenses and other receivables		297		253
Total current assets		6,316		6,139
Property, plant and equipment, net		2,650		2,691
Product acquisition costs, net		1,426		-
Restricted cash, long term		54		54
License fee, net		250		300
Debt issuance costs, net		85		100
Other		155		143
Total assets	$	10,936	$	9,427

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,179	$	1,091
Accrued expenses		1,433		820
Deferred income, current		104		48
Capital lease obligation, current		13		17
Total current liabilities		2,729		1,976

Note payable, bank		2,000		1,000
Deferred income, long term		17		20
Capital lease obligation, long term		-		4
Total liabilities		4,746		3,000

Commitments and contingencies

Stockholders’ equity: Series A Convertible Preferred stock, liquidation preference - $500,000 at June 30, 2013 and December 31, 2012		500		500
Series C Convertible Preferred stock, liquidation preference - $1,802,671 at June 30, 2013 and $1,764,240 at December 31, 2012		1,517		1,517
Common stock		452		446
Additional paid-in capital		47,826		47,409
Accumulated deficit		(44,105)		(43,445)
Total stockholders’ equity		6,190		6,427
Total liabilities and stockholders' equity	$	10,936	$	9,427

The accompanying notes are an integral part of the consolidated financial statements.

* Derived from the audited December 31, 2012 financial statements

IGI LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)


	Six months ended June 30,
	2013		2012
Cash flows from operating activities:
Net loss	$	(660)	$	(1,323)
Reconciliation of net loss to net cash used in operating activities:
Depreciation		190		172
Amortization of license fee		50		50
Stock-based compensation expense		112		164
Provision for write down of inventory		22		61
Amortization of debt issuance costs		15		81
Loss on abandonment of property		-		11
Changes in operating assets and liabilities:
Accounts receivable		(1,025)		(371)
Inventories		(353)		(112)
Prepaid expenses and other assets		(56)		179
Accounts payable and accrued expenses		701		159
Deferred income		53		(2)
Net cash used in operating activities		(951)		(931)

Cash flows from investing activities:
Capital expenditures		(149)		(336)
Product acquisition costs		(1,426)		-
Net cash used in investing activities		(1,575)		(336)

Cash flows from financing activities:
Proceeds from note payable, bank		1,000		-
Principal payments on capital lease obligation		(8)		(22)
Proceeds from exercise of common stock options and warrants		364		26
Costs related to stock issuance		(53)		-
Net cash provided by financing activities		1,303		4

Net decrease in cash and cash equivalents		(1,223)		(1,263)
Cash and cash equivalents at beginning of period		2,536		2,914
Cash and cash equivalents at end of period	$	1,313	$	1,651

Supplemental cash flow information:
Cash payments for interest	$	55	$	64
Cash payment for taxes	$	8	$	9

Non cash investing and financing transactions:
Equipment purchases financed through capital leases	$	-	$	30

The accompanying notes are an integral part of the condensed consolidated financial statements.

IGI LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

For the six months ended June 30, 2013

(in thousands, except share information)


	Series A Preferred Stock		Series C Convertible Preferred Stock		Common Stock		Additional Paid-In Capital	Accumulated Deficit	Total Stockholders’ Equity
	Series A Preferred Stock		Series C Convertible Preferred Stock		Common Stock
	Shares	Amount	Shares	Amount	Shares	Amount

Balance, December 31, 2012 (Audited)	50	$ 500	1,550	$ 1,517	42,705,032	$ 446	$ 47,409	$ (43,445)	$ 6,427

Stock based compensation expense – stock options							103		103
Stock based compensation expense – restricted stock							9		9
Stock warrants exercised					427,713	5	231		236
Stock options exercised					118,670	1	127		128
Costs related to stock issuance							(53)		(53)
Net loss	-	-	-	-	-	-	-	(660)	(660)

Balance, June 30, 2013 (Unaudited)	50	$ 500	1,550	$ 1,517	43,251,415	$ 452	$ 47,826	$ (44,105)	$ 6,190

The accompanying notes are an integral part of the condensed consolidated financial statements.

IGI LABORATORIES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. The condensed consolidated balance sheet as of December 31, 2012 has been derived from those audited consolidated financial statements. Operating results for the three and sixth month period ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.


1.	Organization

	IGI Laboratories, Inc. is a Delaware corporation formed in 1977. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s goal is to become a leader in the generic topical pharmaceutical market. In its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets. The Company’s strategy is based on three initiatives:

	•	Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in its own label in topical dosage forms;
	•	Increasing the Company’s current contract manufacturing and development business; and
	•	Creating unique opportunities through the acquisition of additional intellectual property, and the expansion of the use of the Company’s existing intellectual property, including its licensed Novasome® technology.

	In December, 2012, the Company completed implementation of its commercial infrastructure and launched its first generic topical pharmaceutical products under the IGI label. The Company is now actively marketing three IGI label products. The remainder of product sales are under contract manufacturing agreements. The Company has filed eleven Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA. As discussed in Note 10, on February 1, 2013, the Company acquired product rights to econozale nitrate cream 1%. The Company performs all of its product development and manufacturing at its 25,000 square foot facility in Buena, New Jersey.

2.	Liquidity

	The Company’s principal sources of liquidity are cash and cash equivalents of approximately $1,313,000 at June 30, 2013, the $1,000,000 available under the $3,000,000 credit facility detailed below and cash from operations. The Company sustained net losses of $660,000 and $1,323,000 for the six months ended June 30, 2013 and 2012, respectively, and had working capital of $3,587,000 at June 30, 2013.

	The Company’s business operations have been primarily funded over the past four years through private placements of its capital stock. The Company raised an aggregate of $2,000,000 through private placements of equity with accredited investors in 2012, $7,213,000 in 2010 and $5,304,000 in 2009 principally from private equity investors. The use of proceeds is intended for general working capital needs as well as the acquisition of econozale nitrate cream 1% which was purchased on February 1, 2013. The Company purchased a product and certain product rights which are expected to provide contribution to its gross profit in 2013 (See Note 10). In August 2012, the Company also entered into a $3,000,000 line of credit (See Note 8). In February 2013, the Company drew down an additional $1,000,000 from the available credit facility. As of June 30, 2013, the outstanding balance on the line of credit was $2,000,000. On August 2, 2013, the Company drew down an additional $1,000,000 from the available credit facility. The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that its existing capital resources will be sufficient to support its current business plan and operations for at least the next twelve months.


3.	Summary of Significant Accounting Policies

	*Use of Estimates*

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowance, stock based compensation, provisions for sales returns, chargebacks and other allowances, and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.

	*Loss Per Share*

	Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Due to the net loss for the three months ended June 30, 2013 and 2012 and the six months ended June 30, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each period; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents include options and warrants to purchase the Company’s common stock and the conversion of preferred stock, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 6,049,112 for 2013 and 6,058,641 for 2012.

	*Revenue Recognition*

	The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.

	The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.

	IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.

	Revenue and Provision for Sales Returns and Allowances

	As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.


	The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.

	Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.


Gross-To-Net Sales Deductions	Three months ended June 30,		Six months ended June 30,
	2013	2012	2013	2012

Gross IGI product sales	$ 2,114	$ -	$ 4,380	$ -
Chargebacks	562	-	1,222	-
Sales discounts and other allowances	175	-	365	-
Gross to net adjustments	$ 737	-	$ 1,588	-

Net IGI product sales	$ 1,377	-	$ 2,792	-


	Accounts receivable are presented net of SRA balances of $0.8 million and $0 at June 30, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.4 million and $0 at June 30, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.2 million and $0 for the three month periods ended June 30, 2013 and 2012, respectively, were included in cost of goods sold. Wholesale fees of $0.4 million and $0 for the six month periods ended June 30 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with the three products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.5 million and $0 at June 30, 2013 and 2012, respectively, related to these royalties. Royalty expense of $0.5 million and $0 was included in cost of goods sold for the three months ended June 30, 2013 and 2012, respectively. Royalty expense of $1 million and $0 was included in cost of goods sold for year to date as of June 30 for 2013, and 2012 respectively.

	Product Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products. Sales of the IGI labeled products are recognized when received by the customer. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.

	Research and Development Income: The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.


	In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.

	*Major Customers*

	Major customers of the Company are defined as having revenue greater than 10% of total gross revenue. For the three months ended June 30, 2013, three of the Company’s customers accounted for 41% of the Company’s revenue. For the three months ended June 30, 2012, five of the Company’s customers accounted for 74% of the Company’s revenue. Two of these customers are the same for both periods. For the six months ended June 30, 2013 and 2012, five of the Company’s customers accounted for 67% and three of the Company’s customers accounted for 64% of the Company’s revenue, respectively. Two of these customers are the same for both periods. Accounts receivable related to the Company’s major customers comprised 67% of all accounts receivable as of June 30, 2013. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations.

	*Recent Accounting Pronouncements*

	There were no new accounting pronouncements for the three months ended June 30, 2013 that have a material impact on the Company’s consolidated financial statements.

4.	Inventories

	Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. Inventories at June 30, 2013 and December 31, 2012 consist of:


	June 30, 2013	December 31, 2012
	(Unaudited)	(Audited)
	(amounts in thousands)
Raw materials	$ 1,904	$ 1,673
Work in progress	85	26
Finished goods	115	74
Total	$ 2,104	$ 1,773


5.	Stock-Based Compensation

	Under the 1998 Directors Stock Plan, as amended, 600,000 shares of the Company’s common stock are authorized under the plan and reserved for issuance to non-employee directors, in lieu of payment of directors’ fees in cash. In November 2009, the Company’s Board of Directors approved the elimination of payment of directors’ fees in stock under this plan beginning in the fourth quarter of 2009.

	The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. An aggregate of 1,975,000 shares have been approved and authorized for issuance pursuant to this plan. A total of 2,179,798 options have been granted to non-employee directors through June 30, 2013 and 727,782 of those have been forfeited through June 30, 2013 and returned to the option pool. The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years.

	The 1999 Stock Incentive Plan, as amended (the “1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company's employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years, has been granted at 100% of the fair market value of the Company's common stock at the time of grant. Options outstanding under the 1999 Plan are generally exercisable in cumulative increments over four years commencing one year from the date of grant.


	On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by partial written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company’s current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of common stock available for grant under such plan by adding 2,000,000 shares of common stock. The 2009 Plan, as amended on May 19, 2010, authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of June 30, 2013, options to purchase 1,858,000 shares of common stock were outstanding under the 2009 Plan and 1,148,748 shares of restricted stock had been granted under the 2009 Plan, 230,420 of those have been forfeited through June 30, 2013 and returned to the pool.

	Stock Options

	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. The interest rates used are the U.S. Treasury yield curve in effect at the time of the grant.


			For the three months ended
			June 30, 2013

	Expected volatility		37.5% – 38.3%
	Expected term (in years)		3.2 – 3.3 years
	Risk-free rate		0.43%
	Expected dividends		0%


	A summary of option activity under the 1999 Plan, the Director Plan and the 2009 Plan as of June 30, 2013 and changes during the period are presented below:


	Number of Options	Weighted Average Exercise Price

Outstanding as of January 1, 2013	2,606,500	$1.10
Issued	166,500	$1.12
Exercised	(118,670)	$1.08
Forfeited	(72,330)	$1.33
Expired	-	-
Outstanding as of June 30, 2013	2,582,000	$1.09

Exercisable as of June 30, 2013	1,034,165	$1.17


	Based upon application of the Black-Scholes option-pricing formula described above, the weighted-average grant-date fair value of options granted during the six months ended June 30, 2013 was $0.31.


	The following table summarizes information regarding options outstanding and exercisable at June 30, 2013:


Outstanding:
					Weighted Average
Range of Exercise Prices		Stock Options Outstanding		Weighted Average Exercise Price	Remaining Contractual Life

$0.55	$1.00	218,000	$0.76		5.33
$1.01	$1.50	2,203,000	$1.09		8.40
$1.51	$1.68	161,000	$1.67		7.66
Total		2,582,000	$1.09		8.10


Exercisable:
		Stock Options	Weighted Average
Range of Exercise Prices		Exercisable	Exercise Price

$0.55	$1.00	212,000	$0.75
$1.01	$1.50	672,165	$1.19
$1.51	$1.68	150,000	$1.67
Total		1,034,165	$1.17


	As of June 30, 2013, the intrinsic value of the options outstanding is $904,790 and the intrinsic value of the options exercisable is $302,585. The total intrinsic value of the options exercised during the six months ended June 30, 2013 was $41,654. As of June 30, 2013, there was approximately $345,000 of total unrecognized compensation cost that will be recognized through May 2016 related to non-vested share-based compensation arrangements granted under the equity plans.

	Restricted Stock

	The Company periodically grants restricted stock awards to certain officers and other employees that typically vest one to three years from their grant date. The Company recognized $4,900 and $56,500 of compensation expense during the three months ended June 30, 2013 and 2012, respectively, related to restricted stock awards. Stock compensation expense is recognized over the vesting period of the restricted stock. At June 30, 2013, the Company had approximately $11,400 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized from July 2013 through January 2014.


	Number of Restricted Stock	Weighted Average Exercise Price

Non-vested balance at January 1, 2013	29,334	$ 1.00

Changes during the period:
Shares granted	-	-
Shares vested	-	-
Shares forfeited	-	-

Non-vested balance at June 30, 2013	29,334	$ 1.00


6.	Income Taxes

	As a result of the Company’s history of continuing tax losses, the Company does not have a current tax provision and has recorded a full valuation allowance against its net deferred tax asset. The Company has not recorded a liability for unrecognized tax benefits at June 30, 2013 and no significant changes are expected in the next twelve months. The tax years 2009-2012 remain open to examination by the major taxing jurisdictions to which the Company is subject.


	There was no accrued interest related to unrecognized tax benefits at June 30, 2013.

	The Company’s ability to use net operating loss carry forwards may be subject to substantial limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2009 and 2010, as well as the possibility of such limitation having any material effect on the application of net operating loss carry forwards in the immediate future. The Company believes that it is likely that a change in ownership took place and that the net operating loss carry forwards will be limited.

7.	License Fee

	On December 12, 2005, the Company extended its license agreement for an additional ten years with Novavax, Inc. for $1,000,000. This extension entitles the Company to exclusively use of the Novasome® lipid vesicle encapsulation and certain other technologies in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals, and the processes for making the same through 2015. This payment is being amortized ratably over the ten-year period. The Company recorded amortization expense of $25,000 related to this agreement for each of the three month periods ended June 30, 2013 and 2012 and amortization expense of $50,000 related to this agreement for each of the six months ended June 30, 2013 and 2012.

8.	Note Payable - Bank

	On August 31, 2012, IGI Laboratories, Inc. and its subsidiaries, Igen, Inc. and IGI Labs, Inc., entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Square 1 Bank (the “Lender”) pursuant to which the Lender agreed to extend credit facilities to the Company (the “Financing”). The Company drew down $1,000,000 in principal amount on August 31, 2012 and $1,000,000 in principal amount on February 5, 2013.

	To secure payment of the amounts financed under the Loan and Security Agreement, the Company has granted to the Lender a continuing security interest in and against, generally, all of its tangible and intangible assets, except intellectual property.

	Under the Loan and Security Agreement, the Company can request revolving loan advances under (a) the Formula Revolving Line and (b) the Non-Formula Revolving Line, and term loan advances under the term loans. The aggregate total borrowings under the facilities cannot exceed the total borrowing limit of $3,000,000 at any one time outstanding. Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 1.9% above the prime rate then in effect, and (B) 5.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.15% above the prime rate then in effect, and (B) 5.9%. Term loan advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.4% above the prime rate then in effect, and (B) the rate in effect at December 31, 2012, which was 6.15%.

	The term of the Formula Revolving Line and the Non-Formula Revolving Line is one year from the date of the Loan and Security Agreement and can be extended by mutual agreement of the parties. The term of the term loans is 42 months from the date of the Loan and Security Agreement, but term loan advances are available to the Company only until February 28, 2014.


	In accordance with the Loan and Security Agreement, the Company must maintain a liquidity ratio of at least 1.25 to 1.00 (the “LQR Threshold”), provided that the LQR Threshold shall be reduced to 1.00 to 1.00 so long as the Company has achieved minimum Revenue, measured monthly on a trailing three month basis, of at least the amounts listed in the document for the corresponding reporting periods. To further clarify, if at any time the Company is not in compliance with the minimum revenue amounts set forth below, the LQR Threshold shall be increased to 1.25 to 1.00. “Liquidity” means the sum of: (i) unrestricted cash in bank plus (ii) the Borrowing Base (the amount drawn to date). In accordance with the Loan and Security Agreement, liquidity ratio means the ratio of Liquidity to all Indebtedness to the Lender (but excluding any Indebtedness to the Lender which is secured by cash held in a segregated deposit account at the Lender). As of June 30, 2013, the Company was in compliance with the LQR Threshold required under the Loan and Security Agreement.

	In connection with the Financing, the Company paid in full its existing credit facility with Amzak Capital Management, LLC (see Note 9 below) and executed a Release and Termination Note and Credit Agreement with Amzak Capital Management, LLC to release the Company from any future obligations under the Credit Agreement executed on December 21, 2010 (the “Amzak Credit Facility ”).

	On August 2, 2013, the Company entered into an Amendment to the Loan and Security Agreement (the “Amendment”). In accordance with the Amendment, notwithstanding the existing LQR Thresholds, for so long as the Company is in compliance with the minimum revenue requirements established in this Amendment, the Company shall be permitted to maintain a liquidity ratio of not less than .90 to 1.00 for a continuous 60 day period every 12 months. In connection with the lower liquidity ratio, in accordance with the Amendment, under the Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 4.9% above the prime rate then in effect, and (B) 8.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 5.15% above the prime rate then in effect, and (B) 8.9%, until such time that the lower liquidity ratio is no longer in place. If the Company remains in compliance through the end of December of 2013, the aggregate borrowing amount will be increased from $3,000,000 to $5,000,000. On August 2, 2013, the Company drew down an additional $1,000,000 from the available credit facility.

9.	Stock Warrants

	Stock Warrants activity for the quarters ended June 30, 2013 and 2012 consisted of:


	2013		2012
		Weighted		Weighted
		Average		Average
	Warrants	Exercise Price	Warrants	Exercise Price

Beginning balance	782,259	$0.85	1,235,877	$0.35

Stock warrants granted	-	-	-	-
Stock warrants expired	-	-	-	-
Stock warrants exercised	(427,713)	0.55	-	-

Ending balance	354,546	$1.21	1,235,877	$0.35


	In connection with the private placement of the Company’s Common Stock on December 8, 2010, the Company granted common stock warrants to purchase 338,182 and 16,364 shares, respectively, to each of its two placement agents for $1.21 per share which expire on December 8, 2015. In connection with the private placement of the Company’s common stock in 2012, the Company granted common stock warrants to purchase 387,201 shares for $0.01 per share, which expire December 2022.

	In addition, the Company executed as of December 31, 2012 a settlement agreement with Amzak Capital Management, LLC (“Amzak”) in connection with a common stock purchase warrant issued to Amzak on December 21, 2012 under which the Company issued a ten-year warrant to purchase up to 427,713 shares of the Company’s common stock, with an exercise price of $0.55 per share. The warrants were exercised in full on February 8, 2013. The amount of the fair value of the warrant issued was $209,000, and included as interest expense in 2012, as it related to the credit agreement which was terminated in August of 2012.


10.	Asset Purchase Agreement

	On February 1, 2013, the Company entered into an Asset Purchase Agreement (the “*Purchase Agreement”) with Prasco, LLC, an Ohio limited liability company (“Prasco”), pursuant to which the Company purchased from Prasco assets associated with econazole nitrate cream 1% (the “Product*”), which is available in 15g, 30g, and 85g tubes has United States Food and Drug Administration approved indications for the treatment of tinea pedis, tinea cruris, and tinea corporis as well as the treatment of cutaneous candidiasis and tinea versicolor.

	In consideration for the purchase of the assets pursuant to the Purchase Agreement, the Company paid Prasco $1.4 million in cash and will be required to pay an additional aggregate of $400,000 upon the occurrence of certain milestone events (the “*Milestone Payment*”). The Milestone Payment is secured by a first-priority security interest in the acquired assets under the Purchase Agreement. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment and related costs to acquire the asset are included as part of product acquisition costs totaling $1.4 million. Upon the completion of the milestone payment, the Company will capitalize the remaining milestone payment and related acquisition costs and amortize the costs over fifteen years, the useful life of the acquired product and product rights.

	Under and subject to the terms and conditions of the Purchase Agreement, Prasco will continue to distribute the Product during a six-month period following the closing of the Purchase Agreement or for a shorter period if the Company has completed the technical transfer of the Product and begun manufacturing the Product under its own label. The Company expects sales of the product in the third quarter of 2013.

	In addition, the Purchase Agreement contains certain non-compete restrictions preventing Prasco from selling the Product in United States for a period of seven years.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This "Management's Discussion and Analysis of Financial Condition and Results of Operations" section and other sections of this Quarterly Report on Form 10-Q contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, that are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and on management's beliefs and assumptions. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations of management and are not guarantees of future performance, and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled "Risk Factors" included in our Annual Report on Form 10-K filed on March 28, 2013, as amended, and our Quarterly Report on Form 10-Q filed on May 15, 2013 and any future reports we file with the Securities and Exchange Commission. The forward-looking statements set forth herein speak only as of the date of this report. The Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Company Overview

Strategic Overview

IGI Laboratories is a developer, manufacturer, and marketer of topical formulations. Our goal is to become a leader in the generic topical pharmaceutical market. Under our IGI label, we sell generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. We also provide development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets.

Our strategy is based on three initiatives:

•

Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in our own label in topical dosage forms;

•

Increasing our current contract manufacturing and development business; and

•

Creating unique opportunities through the acquisition of additional intellectual property, and the expansion of the use of our existing intellectual property, including our licensed Novasome ® technology.

In December, 2012, we completed the implementation of our commercial infrastructure and launched our first generic topical pharmaceutical products under the IGI label. We now market three products under our own label. We have filed eleven Abbreviated New Drug Applications, or ANDAs, to date with the United States Food and Drug Administration, or FDA, for additional pharmaceutical products. We filed one application in each of September 2010, January 2011 and December 2011, we filed two applications in each of November 2011, and June 2012, and one application in each of November 2012, January 2013, April 2013 and July 2013. All of the submissions are for generic prescription drugs. Our plan is to continue to expand our presence in the generic topical pharmaceutical market through the filing of additional ANDAs with the FDA and the subsequent launch of products as these applications are approved. Our target is to file six ANDAs per year through our internal research and development program. There is no assurance we will obtain FDA approvals. We will also seek to license or acquire further products, intellectual property, or ANDAs to expand our portfolio. On February 1, 2013, we acquired assets and intellectual property, including an ANDA, for econazole nitrate cream 1%.

IGI also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers as well as the OTC and cosmetic markets. These products are used in a wide range of applications from cosmetics and cosmeceuticals to the prescription treatment of conditions like dermatitis, psoriasis, and eczema.

IGI has structured a new management team to implement this plan, including a new President and CEO, Senior Vice President of Research and Development, Director of Pharmaceutical Operations and a Manager of National Accounts to head up the sales efforts for the newly launched IGI label products. The team brings a wealth of experience in the generic pharmaceutical industry to IGI. IGI’s facilities and manufacturing equipment have been designed to produce topical and liquid products and support the Company’s target prescription dosage forms.

Contract manufacturing services will continue to be crucial to IGI’s success. The customer base for these services is pharmaceutical companies as well as cosmetic, cosmeceutical, and OTC product marketers who require product development/manufacturing support. This is a highly-competitive market with a number of larger, greater-resourced companies offering similar services. IGI looks to create niche opportunities for itself by providing high quality, customer-oriented service.

IGI has exclusive rights for the use of Novasome® technology in topical formulations and intends to pursue collaboration opportunities with established pharmaceutical companies seeking to develop topical products with unique properties. In addition, the Company will explore line extension opportunities through innovative packaging or alternate dosage forms of existing pharmaceutical molecules.

Recent Events

The Company filed three Abbreviated Drug Application, or ANDA, with the U.S. Food and Drug Administration (FDA), one in January 2013, one in April 2013 and one in July 2013.

Results of Operations

Three months ended June 30, 2013 compared to June 30, 2012

The Company had a net loss of $403,000, or $0.01 per share, for the three months ended June 30, 2013, compared to $588,000, or $0.01 per share, in the comparable period for 2012, which resulted from the following:

Revenues (in thousands):


	Three Months Ended June 30,		Increase/(Decrease)
Components of Revenue:	2013	2012	$	%
Product sales	$ 3,706	$ 1,861	$ 1,845	99 %
Research and development income	109	564	(455)	(81)%
Licensing, royalty, and other income	5	12	(7)	(58)%
Total Revenues	$ 3,820	$ 2,437	$ 1,383	57 %

The increase in product sales for the three months ended June 30, 2013 as compared to the same period in 2012 was primarily due to the launch of our own generic pharmaceutical product line, in addition to increased product sales to two of our pharmaceutical customers and two of our cosmetic customers, which was only partially offset by decreased sales to one of our pharmaceutical customers. Research and development income will not be consistent and will vary, from period to period, depending on the required timeline of each development project. The decrease in research and development income during the three months ended June 30, 2013 as compared to the same period in 2012 is attributable primarily to three new customer relationships with pharmaceutical partners established at the end of 2011 and the beginning of 2012. We completed several site transfers, formulation services, 510 (k) submissions for medical devices and filing of two ANDAs for these customers in 2012. Licensing, royalty and other revenue decreased due to a decrease in other revenue while licensing and royalty revenue remained the same.

Costs and expenses (in thousands):


	Three Months Ended June 30,		Increase/(Decrease)
	2013	2012	$	%
Cost of sales	$ 2,673	$ 1,683	$ 990	59%
Selling, general and administrative	706	615	91	15%
Product development and research	805	644	161	25%
Totals costs and expenditures	$ 4,184	$ 2,942	$ 1,242	42%

Cost of sales increased for the three months ended June 30, 2013 as a result of the increase in total revenue. Cost of sales as a percentage of total revenue was 70% for the three months ended June 30, 2013 as compared to 69% for the three months ended June 30, 2012. Cost of sales as a percentage of product sales was consistent with the prior period, as result of a shift in the mix of our product sales to include greater higher margin pharmaceutical products as well as revenue from our the launch of first three IGI label products, which was however offset by the decline in research and development income. Our research and development income results primarily from services rendered under contractual agreements, and therefore cost of sales as a percentage of our research and development income is relatively low. Consistent with our strategy, we expect cost of sales as a percentage of total revenue to decline over time.

Selling, general and administrative expenses for the three months ended June 30, 2013 increased by $91,000 as compared to the same period in 2012. There were increases in salaries and related costs of $30,000, professional fees of $30,000, consulting fees of $12,000, trade show expenses of $11,000 and travel related costs of $7,000 during the three months ended June 30, 2013 as compared to the same period in 2012.

Product development and research expenses for the three months ended June 30, 2013 increased by $161,000 as compared to the same period in 2012. Consistent with our strategy to expand our portfolio of generic prescription topical pharmaceutical products, we increased headcount, which resulted in an increase of $36,000 in salaries and related costs, we increased spending on clinical studies, outside testing, pilot batch expense and supplies by $138,000 and professional fees by $10,000. In addition, we incurred approximately $52,000 in fees related to the Generic Drug User Fee Act, and the associated filing of our applications with the FDA. These increases were partially offset by a decrease of $80,000 in consulting fees.

Interest (Income) Expense (in thousands):


	Three Months Ended June 30,		Increase/(Decrease)
	2013	2012	$	%
Interest Expense	$ 39	$ 72	$ (33)	(46)%
Other Expense	$ -	$ 11	$ (11)	(100)%

Interest expense decreased for the three months ended June 30, 2013 as compared to the same period in 2012 due to the lower interest rate on the Note Payable – Bank (see Note 8 to the Company’s Consolidated Financial Statements) that was outstanding for the three months ended June 30, 2013 as compared to the interest rate on the Notes Payable that was outstanding in the comparable period in 2012.

Net loss (in thousands, except per share numbers):


	Three Months Ended June 30,		Increase/(Decrease)
	2013	2012	$	%
Net loss	$ (403)	$ (588)	$ (185)	(31)%
Net loss per share	$ (.01)	$ (.01)	$ -	0%

The decrease in net loss for the three months ended June 30, 2013 as compared to the same period in 2012 is due to the increase in revenues partially offset by the increases in costs and expenses noted above.

Six months ended June 30, 2013 compared to June 30, 2012

The Company had a net loss of $660,000, or $0.02 per share, for the six months ended June 30, 2013, compared to $1,323,000, or $0.03 per share, in the comparable period in 2012, which resulted from the following:

Revenues (in thousands):


	Six Months Ended June 30,		Increase/(Decrease)
Components of Revenue:	2013	2012	$	%
Product sales	$ 7,174	$ 3,371	$ 3,803	113 %
Research and development income	268	872	(604)	(69)%
Licensing, royalty and other income	62	26	36	138 %
Total Revenues	$ 7,504	$ 4,269	$ 3,235	76 %

The increase in product sales for the six months ended June 30, 2013 as compared to the same period in 2012 was primarily due to the launch of our own generic pharmaceutical product line, in addition to increased product sales to two of our pharmaceutical customers and one of our cosmetic customers, which was only partially offset by decreased sales to one of our pharmaceutical customers. Research and development income will not be consistent and will vary, from period to period, depending on the required timeline of each development project. The decrease in research and development income during the six months ended June 30, 2013 as compared to the same period in 2012 is attributable primarily to three new customer relationships with pharmaceutical partners established at the end of 2011 and the beginning of 2012. We completed several site transfers, formulation services, 510 (k) submissions for medical devices and filing of two ANDAs for these customers in 2012. Licensing, royalty and other revenue increased due to an increase in other revenue while licensing and royalty revenue remained the same.

Costs and expenses (in thousands):


	Six Months Ended June 30,		Increase/(Decrease)
	2013	2012	$	%
Cost of sales	$ 5,248	$ 3,049	$ 2,199	72%
Selling, general and administrative	1,386	1,273	113	25%
Product development and research	1,463	1,116	347	9%
Totals costs and expenditures	$ 8,097	$ 5,438	$ 2,659	49%

Cost of sales increased for the six months ended June 30, 2013 as a result of the increase in total revenue. Cost of sales as a percentage of total revenue was 70% for the six months ended June 30, 2013 as compared to 71% for the six months ended June 30, 2012. Cost of sales as a percentage of total revenue declined as a result of a shift in the mix of our product sales to include greater higher margin pharmaceutical products, and our increase in revenue which was only partially offset by the decline in product development and research income. We expect cost of sales as a percentage of product sales to decline over time.

Selling, general and administrative expenses for the six months ended June 30, 2013 increased by $113,000 as compared to the same period in 2012. There were increases in salaries and related costs of $62,000, professional fees of $58,000, trade show expenses of $21,000 and travel related costs of $12,000 and overhead costs of $10,000 during the six months ended June 30, 2013 as compared to the same period in 2012. These increases were partially offset by a decrease of $59,000 in recruiting fees and a decrease of $13,000 in commissions.

Product development and research expenses for the six months ended June 30, 2013 increased by $347,000 as compared to the same period in 2012. Consistent with our strategy to expand our portfolio of generic prescription topical pharmaceutical products, we increased headcount, which resulted in an increase of $128,000 in salaries and related costs, we increased spending on clinical studies, outside testing, pilot batch expense and supplies by $163,000, professional fees by $35,000 and overhead costs by $15,000. In addition, we incurred approximately $106,000 in fees related to the Generic Drug User Fee Act, and the associated filing of our applications with the FDA. These increases were partially offset by a decrease of $98,000 in consulting fees.

Interest (Income) Expense and Other Income (in thousands):


	Six Months Ended June 30,		Increase/(Decrease)
	2013	2012	$	%
Interest Expense	$ 72	$ 144	$ (72)	(50)%
Other (Income) Expense	$ (5)	$ 10	$ (15)	(150)%

Interest expense decreased for the six months ended June 30, 2013 as compared to the same period in 2012 due to the lower interest rate on the Note Payable – Bank (see Note 8 to the Company’s Consolidated Financial Statements) that was outstanding for the six months ended June 30, 2013 as compared to the interest rate on the Notes Payable that was outstanding in the comparable period in 2012.

Net loss (in thousands, except per share numbers):


	Six Months Ended June 30,		Increase/(Decrease)
	2013	2012	$	%
Net loss	$ (660)	$ (1,323)	$ (700)	(53)%
Net loss per share	$ (.02)	$ (.03)	$ (.01)	(33)%

The decrease in net loss for the six months ended June 30, 2013 as compared to the same period in 2012 is due to the increase in revenues partially offset by the increases in costs and expenses noted above.

Liquidity and Capital Resources

The Company's operating activities used $951,000 of cash during the six months ended June 30, 2013 compared to $931,000 used in the comparable period of 2012. The use of cash for both the six months ended June 30, 2013 and 2012 was substantially a result of the net loss for each period, which included costs related to product development and research of $1.5 million and $1.1 million for the six months ended June 30, 2013 and 2012, respectively.

The Company’s investing activities used $1.6 million of cash in the six months ended June 30, 2013 compared to $0.3 million of cash used in investing activities in the first six months of 2012. The funds used for the period ended June 30, 2013 were for the purchase of econazole nitrate cream (see Note 10 to the Company’s Consolidated Financial Statements) and additional equipment and improvements in the compounding area and packaging and filling lines and the funds used for the period ended June 30, 2012 were for additional equipment and improvements for the packaging and filling lines and additional equipment and related services for the analytical area.

The Company's financing activities provided $1,303,000 of cash in the six months ended June 30, 2013 compared to $4,000 provided in the six months ended June 30, 2012. The cash provided for the six month period ended June 30, 2012 was mainly the proceeds of $1,000,000 from the drawdown of the Note Payable (see Note 8 to the Company’s Consolidated Financial Statements) and $364,000 of proceeds from the exercise of options and warrants to purchase common stock. The cash provided for the six month period ended June 30, 2012 was the proceeds from the exercise of stock options less payments on capital lease obligations.

The Company’s principal sources of liquidity are cash and cash equivalents of approximately $1.3 million at June 30, 2013 and future cash from operations. The Company had working capital of $3.6 million at June 30, 2013.

The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity or through a strategic alliance with a third party. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. We believe that our existing capital resources, including the remaining $1 million availability under the line of credit detailed in Note 8, will be sufficient to support our current business plan for the next 12 months as indicated in the Financial Statements.

Off Balance Sheet Arrangements

The Company does not have any off balance sheet arrangements as of June 30, 2013.

Critical Accounting Policies and Estimates

IGI’s condensed consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles, which require management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from these estimates.

Please refer to the Company’s Form 10-K for the year ended December 31, 2012 for a complete list of all Critical Accounting Policies and Estimates. See also Note 3 to the Company’s Condensed Consolidated Financial Statements.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Our management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2013. Based on that evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that, as of June 30, 2013, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial and Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during our second quarter ended June 30, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

OTHER INFORMATION

ITEM 1. Legal Proceedings

We are involved from time to time in claims which arise in the ordinary course of business. In the opinion of management, we have made adequate provision for potential liabilities, if any, arising from any such matters. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings (whether civil or criminal), settlements, judgments and investigations, claims and changes in any such matters, and developments or assertions by or against us relating to intellectual property rights and intellectual property licenses, could have a material adverse effect on our business, financial condition and operating results.

ITEM 1A. Risk Factors.

Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2012 includes a detailed discussion of risks and uncertainties which could adversely affect our future results. Except as set forth below, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2012, as updated in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, have not materially changed.

Risks Related to Our Business

We rely on a limited number of customers for a large portion of our revenues.

We depend on a limited number of customers for a large portion of our revenue. For the three months ended June 30, 2013 and 2012, three of our customers accounted for 41% and five of our customers accounted for 74% of our revenue, respectively. For the six months ended June 30, 2013 and 2012, five of our customers accounted for 67% and three of our customers accounted for 64% of our revenue, respectively. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations.

We have a history of losses and cannot assure you that we will become profitable, and as a result, we may have to cease operations and liquidate our business.

Our expenses have exceeded our revenue in each of the last nine years, and no net income has been available to common stockholders during each of these years. As of June 30, 2013, our stockholders’ equity was $6.2 million and we had an accumulated deficit of $44 million. Our future profitability depends on revenue exceeding expenses, but we cannot assure you that this will occur. If we do not become profitable or continue to raise external financing, we could be forced to curtail operations and sell or liquidate our business, and you could lose some or all of your investment.

Risks Related to Our Securities

Shares of our common stock are relatively illiquid which may affect the trading price of our common stock.

For the six months ended June 30, 2013, the average daily trading volume of our common stock on the NYSE MKT was approximately 45,000 shares. As a result of our relatively small public float, our common stock may be less liquid than the stock of companies with broader public ownership. Among other things, trading of a relatively small volume of our common stock may have a greater impact on the trading price for our shares than would be the case if our public float were larger.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

N/A

ITEM 5. Other Information

None.

ITEM 6. Exhibits


Exhibit Number		Description

31.1*		Certification of the President and Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial information from this Quarterly Report on Form 10-Q for the period ended June 30, 2013, formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Statements of Operations; (ii) the Condensed Consolidated Balance Sheets; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Consolidated Financial Statements, tagged as blocks of text.

Filed herewith.

Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	IGI Laboratories, Inc.

Date: August 14, 2013	By:	/s/ Jason Grenfell-Gardner
		Jason Grenfell-Gardner
		President and Chief Executive Officer

Date: August 14, 2013	By:	/s/ Jenniffer Collins
		Jenniffer Collins
		Chief Financial Officer

Exhibit Index


Exhibit Number		Description

31.1*		Certification of the President and Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial information from this Quarterly Report on Form 10-Q for the period ended June 30, 2013, formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Statements of Operations; (ii) the Condensed Consolidated Balance Sheets; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Consolidated Financial Statements, tagged as blocks of text.

Filed herewith.

Furnished herewith.

EX-31 2 ex311.htm EXHIBIT 31.1 Exhibit 31

Exhibit 31.1

CERTIFICATION

JASON GRENFELL-GARDNER

PRESIDENT AND CHIEF EXECUTIVE OFFICER

IGI LABORATORIES, INC.

I, Jason Grenfell-Gardner, President and Chief Executive Officer of IGI Laboratories, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of IGI Laboratories, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2013


	/s/	Jason Grenfell-Gardner
		Jason Grenfell-Gardner
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31 3 ex312.htm EXHIBIT 31.2 Converted by EDGARwiz

Exhibit 31.2

CERTIFICATION

JENNIFFER COLLINS

CHIEF FINANCIAL OFFICER

IGI LABORATORIES, INC.

I, Jenniffer Collins, Chief Financial Officer of IGI Laboratories, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of IGI Laboratories, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2013


	/s/	Jenniffer Collins
		Jenniffer Collins
		Chief Financial Officer
		(Principal Financial Officer)

EX-32 4 ex321.htm EXHIBIT 32.1 Converted by EDGARwiz

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IGI Laboratories, Inc. (the “Company”) on Form 10-Q for the quarterly ended June 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jason
Grenfell-Gardner, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2013


	/s/	Jason Grenfell-Gardner
		Jason Grenfell-Gardner
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-32 5 ex322.htm EXHIBIT 32.2 Converted by EDGARwiz

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IGI Laboratories, Inc. (the “Company”) on Form 10-Q for the quarterly ended June 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jenniffer Collins, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2013


	/s/	Jenniffer Collins
		Jenniffer Collins
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 6 ig-20130630.xml 0000352998 2013-04-01 2013-06-30 0000352998 2012-04-01 2012-06-30 0000352998 2013-01-01 2013-06-30 0000352998 2012-01-01 2012-06-30 0000352998 2013-06-30 0000352998 2012-12-31 0000352998 us-gaap:SeriesAPreferredStockMember 2013-06-30 0000352998 us-gaap:SeriesAPreferredStockMember 2012-12-31 0000352998 us-gaap:SeriesCPreferredStockMember 2013-06-30 0000352998 us-gaap:SeriesCPreferredStockMember 2012-12-31 0000352998 2011-12-31 0000352998 2012-06-30 0000352998 us-gaap:PreferredStockMember 2012-12-31 0000352998 us-gaap:ConvertiblePreferredStockMember 2012-12-31 0000352998 us-gaap:CommonStockMember 2012-12-31 0000352998 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000352998 us-gaap:RetainedEarningsMember 2012-12-31 0000352998 ig:StockOptionsotherthanrestrictedstockMember us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-06-30 0000352998 ig:StockOptionsotherthanrestrictedstockMember 2013-01-01 2013-06-30 0000352998 us-gaap:RestrictedStockMember us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-06-30 0000352998 us-gaap:RestrictedStockMember 2013-01-01 2013-06-30 0000352998 us-gaap:CommonStockMember 2013-01-01 2013-06-30 0000352998 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-06-30 0000352998 us-gaap:RetainedEarningsMember 2013-01-01 2013-06-30 0000352998 us-gaap:PreferredStockMember 2013-06-30 0000352998 us-gaap:ConvertiblePreferredStockMember 2013-06-30 0000352998 us-gaap:CommonStockMember 2013-06-30 0000352998 us-gaap:AdditionalPaidInCapitalMember 2013-06-30 0000352998 us-gaap:RetainedEarningsMember 2013-06-30 0000352998 2013-08-02 0000352998 2012-01-01 2012-12-31 0000352998 2010-01-01 2010-12-31 0000352998 2009-01-01 2009-12-31 0000352998 2012-08-31 0000352998 2013-02-01 2013-02-28 0000352998 us-gaap:SubsequentEventMember 2013-08-01 2013-08-02 0000352998 us-gaap:MinimumMember 2013-06-30 0000352998 us-gaap:MaximumMember 2013-06-30 0000352998 ig:NetofSRABalanceMember 2013-06-30 0000352998 ig:NetofSRABalanceMember 2012-06-30 0000352998 ig:RelatedtoRoyaltiesMember 2013-06-30 0000352998 ig:RelatedtoRoyaltiesMember 2012-06-30 0000352998 ig:GrosstoNetAdjustmentsMember 2013-04-01 2013-06-30 0000352998 ig:GrosstoNetAdjustmentsMember 2013-01-01 2013-06-30 0000352998 ig:NineteenNinetyEightDirectorsStockPlanMember 2009-12-31 0000352998 ig:NineteenNinetyNineDirectorsStockPlanMember 2009-12-31 0000352998 ig:NineteenNinetyNineDirectorsStockPlanMember 1999-01-01 2013-06-30 0000352998 ig:NineteenNinetyNineDirectorsStockPlanMember 2013-01-01 2013-06-30 0000352998 ig:NineteenNinetyNineDirectorsStockPlanMember 2013-06-30 0000352998 ig:NineteenNinetyNineStockIncentivePlanMember 2013-06-30 0000352998 ig:NineteenNinetyNineStockIncentivePlanMember 1999-01-01 2013-06-30 0000352998 1999-01-01 2009-12-31 0000352998 ig:NineteenNinetyNineStockIncentivePlanMember 2013-01-01 2013-06-30 0000352998 2010-04-01 2010-04-12 0000352998 ig:TwoThousandNineEquityIncentivePlanMember 2010-05-19 0000352998 ig:TwoThousandNineEquityIncentivePlanMember ig:MaximumNumberOfSharesAllowedPerYearMember 2010-05-19 0000352998 us-gaap:RestrictedStockMember ig:TwoThousandNineEquityIncentivePlanMember 2010-05-19 0000352998 us-gaap:RestrictedStockMember ig:TwoThousandNineEquityIncentivePlanMember 2013-01-01 2013-06-30 0000352998 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2013-01-01 2013-06-30 0000352998 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2013-01-01 2013-06-30 0000352998 us-gaap:RestrictedStockMember 2013-04-01 2013-06-30 0000352998 us-gaap:RestrictedStockMember 2013-06-30 0000352998 us-gaap:MinimumMember 2013-01-01 2013-06-30 0000352998 us-gaap:MaximumMember 2013-01-01 2013-06-30 0000352998 us-gaap:MinimumMember ig:Range55100Member 2013-01-01 2013-06-30 0000352998 us-gaap:MaximumMember ig:Range55100Member 2013-01-01 2013-06-30 0000352998 ig:Range55100Member 2013-06-30 0000352998 ig:Range55100Member 2013-01-01 2013-06-30 0000352998 us-gaap:MinimumMember ig:Range101150Member 2013-01-01 2013-06-30 0000352998 us-gaap:MaximumMember ig:Range101150Member 2013-01-01 2013-06-30 0000352998 ig:Range101150Member 2013-06-30 0000352998 ig:Range101150Member 2013-01-01 2013-06-30 0000352998 us-gaap:MinimumMember ig:Range151to168Member 2013-01-01 2013-06-30 0000352998 us-gaap:MaximumMember ig:Range151to168Member 2013-01-01 2013-06-30 0000352998 ig:Range151to168Member 2013-06-30 0000352998 ig:Range151to168Member 2013-01-01 2013-06-30 0000352998 ig:ExercisableMember ig:Range55100Member 2013-01-01 2013-06-30 0000352998 ig:ExercisableMember ig:Range101150Member 2013-01-01 2013-06-30 0000352998 ig:ExercisableMember ig:Range1Dollar51CentsTo1Dollar68CentsMember 2013-01-01 2013-06-30 0000352998 ig:Range1Dollar51CentsTo1Dollar68CentsMember 2013-06-30 0000352998 2005-12-12 0000352998 us-gaap:LicensingAgreementsMember 2013-04-01 2013-06-30 0000352998 us-gaap:LicensingAgreementsMember 2012-04-01 2012-06-30 0000352998 us-gaap:LicensingAgreementsMember 2013-01-01 2013-06-30 0000352998 us-gaap:LicensingAgreementsMember 2012-01-01 2012-06-30 0000352998 2012-08-01 2012-08-31 0000352998 2013-02-04 2013-02-05 0000352998 ig:FormulaRevolvingLineMember ig:AbovePrimeRateMember 2013-01-01 2013-06-30 0000352998 ig:NonFormulaRevolvingLineMember 2013-01-01 2013-06-30 0000352998 ig:FormulaRevolvingLineMember 2013-01-01 2013-06-30 0000352998 ig:NonFormulaRevolvingLineMember us-gaap:MaximumMember 2013-01-01 2013-06-30 0000352998 ig:FormulaRevolvingLineMember ig:AbovePrimeRateMember 2013-01-01 2013-06-30 0000352998 ig:NonFormulaRevolvingLineMember 2012-01-01 2012-12-31 0000352998 us-gaap:MaximumMember us-gaap:SubsequentEventMember 2013-07-01 2013-07-26 0000352998 ig:FormulaRevolvingLineMember ig:AbovePrimeRateMember us-gaap:SubsequentEventMember 2013-07-01 2013-07-26 0000352998 ig:NonFormulaRevolvingLineMember us-gaap:SubsequentEventMember 2013-07-01 2013-07-26 0000352998 ig:FormulaRevolvingLineMember us-gaap:SubsequentEventMember 2013-07-01 2013-07-26 0000352998 ig:NonFormulaRevolvingLineMember us-gaap:MaximumMember us-gaap:SubsequentEventMember 2013-07-01 2013-07-26 0000352998 ig:CompanyRemainsInComplianceThroughDecember2013Member us-gaap:SubsequentEventMember 2013-07-26 0000352998 ig:FirstPlacementAgentMember 2010-12-08 0000352998 ig:SecondPlacementAgentMember 2010-12-08 0000352998 2010-12-08 0000352998 ig:WarrantsIssuedInConnectionWithPrivatePlacementOfferingMember 2003-03-31 0000352998 ig:WarrantsIssuedInConnectionWithPrivatePlacementOfferingMember 2013-02-08 0000352998 2013-02-08 0000352998 2013-03-31 0000352998 2012-03-31 0000352998 2013-02-01 2013-02-02 0000352998 2013-02-02 iso4217:USD iso4217:USD xbrli:shares xbrli:shares utr:sqft xbrli:pure iso4217:USD compsci:item Derived from the audited December 31, 2012 financial statements

3706000

1861000

7174000

3371000

109000

564000

268000

872000

5000 12000 62000 26000

3820000

2437000

7504000

4269000

2673000

1683000

5248000

3049000

706000

615000

1386000

1273000

805000

644000

1463000

1116000

4184000

2942000

8097000

5438000

-364000

-505000

-593000

-1169000

-39000

-83000

-67000

-154000

-403000

-588000

-660000

-1323000

-0.01

-0.02

-0.03

43206016

39522868

43070335

39511745

2536000

2602000

1577000

2104000

1773000

297000

253000

6316000

6139000

2650000

2691000

1426000

54000

250000

300000

85000

100000

155000

143000

10936000

9427000

1179000

1091000

1433000

820000

104000

48000

13000

17000

2729000

1976000

2000000

1000000

17000

20000

4000

4746000

3000000

500000

1517000

452000

446000

47826000

47409000

-44105000

-43445000

6190000

6427000

10936000

9427000

500000

1802671

1764240

190000

172000

50000

112000

164000

22000

61000

15000

81000

-11000

1025000

371000

353000

112000

56000

-179000

701000

159000

53000

-2000

-951000

-931000

149000

336000

-1426000

-1575000

-336000

1000000

8000

22000

364000 26000

53000

1303000

4000

-1223000

-1263000

2914000

1651000

55000

64000

8000

9000

30000

500000

1550

1517000

42705032

446000

47409000

-43445000

103000

9000

427713

5000

231000

236000

118670

1000

127000

128000

-53000

-660000

500000

1550

1517000

43251415

452000

47826000

-44105000

IGI Laboratories, Inc. 10-Q --12-31 43251415 false 0000352998 Yes No Smaller Reporting Company No 2013 Q2 2013-06-30

1.      Organization IGI Laboratories, Inc. is a Delaware corporation formed in 1977. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s goal is to become a leader in the generic topical pharmaceutical market. In its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets. The Company’s strategy is based on three initiatives: <table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="MTAB496" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="WIDTH: 18pt">   </td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> ● </td> <td style="VERTICAL-ALIGN: top"> Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in its own label in topical dosage forms; </td> </tr> <tr> <td style="WIDTH: 18pt">   </td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> ● </td> <td style="VERTICAL-ALIGN: top"> Increasing the Company’s current contract manufacturing and development business; and </td> </tr> </table> <table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="MTAB500" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="WIDTH: 18pt">   </td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> ● </td> <td style="VERTICAL-ALIGN: top"> Creating unique opportunities through the acquisition of additional intellectual property, and the expansion of the use of the Company’s existing intellectual property, including its licensed Novasome® technology. </td> </tr> </table> In December, 2012, the Company completed implementation of its commercial infrastructure and launched its first generic topical pharmaceutical products under the IGI label. The Company is now actively marketing three IGI label products. The remainder of product sales are under contract manufacturing agreements. The Company has filed eleven Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA. As discussed in Note 10, on February 1, 2013, the Company acquired product rights to econozale nitrate cream 1%. The Company performs all of its product development and manufacturing at its 25,000 square foot facility in Buena, New Jersey.

25000

2.      Liquidity The Company’s principal sources of liquidity are cash and cash equivalents of approximately $1,313,000 at June 30, 2013, the $1,000,000 available under the $3,000,000 credit facility detailed below and cash from operations. The Company sustained net losses of $660,000 and $1,323,000 for the six months ended June 30, 2013 and 2012, respectively, and had working capital of $3,587,000 at June 30, 2013. The Company’s business operations have been primarily funded over the past four years through private placements of its capital stock. The Company raised an aggregate of $2,000,000 through private placements of equity with accredited investors in 2012, $7,213,000 in 2010 and $5,304,000 in 2009 principally from private equity investors. The use of proceeds is intended for general working capital needs as well as the acquisition of econozale nitrate cream 1% which was purchased on February 1, 2013. The Company purchased a product and certain product rights which are expected to provide contribution to its gross profit in 2013 (See Note 10). In August 2012, the Company also entered into a $3,000,000 line of credit (See Note 8). In February 2013, the Company drew down an additional $1,000,000 from the available credit facility. As of June 30, 2013, the outstanding balance on the line of credit was $2,000,000. On August 2, 2013, the Company drew down an additional $1.0 million from the available credit facility. The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that its existing capital resources will be sufficient to support its current business plan and operations for at least the next twelve months.

1313000

1000000

3000000

-660000

-1323000

3587000

2000000

7213000

5304000

3000000

1000000

2000000

3.      Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowance, stock based compensation, provisions for sales returns, chargebacks and other allowances, and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates. Loss Per Share Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Due to the net loss for the three months ended June 30, 2013 and 2012 and the six months ended June 30, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each period; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents include options and warrants to purchase the Company’s common stock and the conversion of preferred stock, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 6,049,112 for 2013 and 6,058,641 for 2012. Revenue Recognition The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition. The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties.  Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer. Revenue and Provision for Sales Returns and Allowances As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.  The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses. <table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL998" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 44%; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid"> Gross-To-Net Sales Deductions </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B5">   </td> </tr> <tr> <td style="WIDTH: 44%">   </td> <td id="TBL998.finRow.2.lead.B2">   </td> <td id="TBL998.finRow.2.symb.B2">   </td> <td id="TBL998.finRow.2.amt.B2">   </td> <td id="TBL998.finRow.2.trail.B2">   </td> <td id="TBL998.finRow.2.lead.B3">   </td> <td id="TBL998.finRow.2.symb.B3">   </td> <td id="TBL998.finRow.2.amt.B3">   </td> <td id="TBL998.finRow.2.trail.B3">   </td> <td id="TBL998.finRow.2.lead.B4">   </td> <td id="TBL998.finRow.2.symb.B4">   </td> <td id="TBL998.finRow.2.amt.B4">   </td> <td id="TBL998.finRow.2.trail.B4">   </td> <td id="TBL998.finRow.2.lead.B5">   </td> <td id="TBL998.finRow.2.symb.B5">   </td> <td id="TBL998.finRow.2.amt.B5">   </td> <td id="TBL998.finRow.2.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: center; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.lead.D2">   </td> <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.3.amt.D2" colspan="6"> Three months ended June 30, </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.trail.B3">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.lead.D4">   </td> <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.3.amt.D4" colspan="6"> Six months ended June 30, </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: right; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D2">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D2" colspan="2"> 2013 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D2">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D3">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D3" colspan="2"> 2012 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D3">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D4">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D4" colspan="2"> 2013 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D4">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D5">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D5" colspan="2"> 2012 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D5">   </td> </tr> <tr> <td style="WIDTH: 44%">   </td> <td id="TBL998.finRow.5.lead.B2">   </td> <td id="TBL998.finRow.5.symb.B2">   </td> <td id="TBL998.finRow.5.amt.B2">   </td> <td id="TBL998.finRow.5.trail.B2">   </td> <td id="TBL998.finRow.5.lead.B3">   </td> <td id="TBL998.finRow.5.symb.B3">   </td> <td id="TBL998.finRow.5.amt.B3">   </td> <td id="TBL998.finRow.5.trail.B3">   </td> <td id="TBL998.finRow.5.lead.B4">   </td> <td id="TBL998.finRow.5.symb.B4">   </td> <td id="TBL998.finRow.5.amt.B4">   </td> <td id="TBL998.finRow.5.trail.B4">   </td> <td id="TBL998.finRow.5.lead.B5">   </td> <td id="TBL998.finRow.5.symb.B5">   </td> <td id="TBL998.finRow.5.amt.B5">   </td> <td id="TBL998.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Gross IGI product sales </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.2"> 2,114 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.4"> 4,380 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Chargebacks </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.2"> 562 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.4"> 1,222 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Sales discounts and other allowances </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.2"> 175 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.4"> 365 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Gross to net adjustments </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.2"> 737 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.4"> 1,588 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 44%">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B5">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Net IGI product sales </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.2"> 1,377 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.4"> 2,792 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.5" nowrap="nowrap">   </td> </tr> </table> Accounts receivable are presented net of SRA balances of $0.8 million and $0 at June 30, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.4 million and $0 at June 30, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.2 million and $0 for the three month periods ended June 30, 2013 and 2012, respectively, were included in cost of goods sold. Wholesale fees of $0.4 million and $0 for the six month periods ended June 30 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with the three products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.5 million and $0 at June 30, 2013 and 2012, respectively, related to these royalties. Royalty expense of $0.5 million and $0 was included in cost of goods sold for the three months ended June 30, 2013 and 2012, respectively. Royalty expense of $1 million and $0 was included in cost of goods sold for year to date as of June 30 for 2013, and 2012 respectively. Product Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products. Sales of the IGI labeled products are recognized when received by the customer. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs. Research and Development Income:  The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.   In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company. Major Customers Major customers of the Company are defined as having revenue greater than 10% of total gross revenue. For the three months ended June 30, 2013, three of the Company’s customers accounted for 41% of the Company’s revenue. For the three months ended June 30, 2012, five of the Company’s customers accounted for 74% of the Company’s revenue. Two of these customers are the same for both periods. For the six months ended June 30, 2013 and 2012, five of the Company’s customers accounted for 67% and three of the Company’s customers accounted for 64% of the Company’s revenue, respectively. Two of these customers are the same for both periods. Accounts receivable related to the Company’s major customers comprised 67% of all accounts receivable as of June 30, 2013. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations. Recent Accounting Pronouncements There were no new accounting pronouncements for the three months ended June 30, 2013 that have a material impact on the Company’s consolidated financial statements.

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowance, stock based compensation, provisions for sales returns, chargebacks and other allowances, and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.

Loss Per Share Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Due to the net loss for the three months ended June 30, 2013 and 2012 and the six months ended June 30, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each period; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents include options and warrants to purchase the Company’s common stock and the conversion of preferred stock, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 6,049,112 for 2013 and 6,058,641 for 2012.

6049112

6058641

Revenue Recognition The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition. The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties.  Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer. Revenue and Provision for Sales Returns and Allowances As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.  The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses. <table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL998" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 44%; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid"> Gross-To-Net Sales Deductions </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B5">   </td> </tr> <tr> <td style="WIDTH: 44%">   </td> <td id="TBL998.finRow.2.lead.B2">   </td> <td id="TBL998.finRow.2.symb.B2">   </td> <td id="TBL998.finRow.2.amt.B2">   </td> <td id="TBL998.finRow.2.trail.B2">   </td> <td id="TBL998.finRow.2.lead.B3">   </td> <td id="TBL998.finRow.2.symb.B3">   </td> <td id="TBL998.finRow.2.amt.B3">   </td> <td id="TBL998.finRow.2.trail.B3">   </td> <td id="TBL998.finRow.2.lead.B4">   </td> <td id="TBL998.finRow.2.symb.B4">   </td> <td id="TBL998.finRow.2.amt.B4">   </td> <td id="TBL998.finRow.2.trail.B4">   </td> <td id="TBL998.finRow.2.lead.B5">   </td> <td id="TBL998.finRow.2.symb.B5">   </td> <td id="TBL998.finRow.2.amt.B5">   </td> <td id="TBL998.finRow.2.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: center; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.lead.D2">   </td> <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.3.amt.D2" colspan="6"> Three months ended June 30, </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.trail.B3">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.lead.D4">   </td> <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.3.amt.D4" colspan="6"> Six months ended June 30, </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: right; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D2">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D2" colspan="2"> 2013 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D2">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D3">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D3" colspan="2"> 2012 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D3">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D4">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D4" colspan="2"> 2013 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D4">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D5">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D5" colspan="2"> 2012 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D5">   </td> </tr> <tr> <td style="WIDTH: 44%">   </td> <td id="TBL998.finRow.5.lead.B2">   </td> <td id="TBL998.finRow.5.symb.B2">   </td> <td id="TBL998.finRow.5.amt.B2">   </td> <td id="TBL998.finRow.5.trail.B2">   </td> <td id="TBL998.finRow.5.lead.B3">   </td> <td id="TBL998.finRow.5.symb.B3">   </td> <td id="TBL998.finRow.5.amt.B3">   </td> <td id="TBL998.finRow.5.trail.B3">   </td> <td id="TBL998.finRow.5.lead.B4">   </td> <td id="TBL998.finRow.5.symb.B4">   </td> <td id="TBL998.finRow.5.amt.B4">   </td> <td id="TBL998.finRow.5.trail.B4">   </td> <td id="TBL998.finRow.5.lead.B5">   </td> <td id="TBL998.finRow.5.symb.B5">   </td> <td id="TBL998.finRow.5.amt.B5">   </td> <td id="TBL998.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Gross IGI product sales </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.2"> 2,114 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.4"> 4,380 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Chargebacks </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.2"> 562 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.4"> 1,222 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Sales discounts and other allowances </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.2"> 175 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.4"> 365 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Gross to net adjustments </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.2"> 737 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.4"> 1,588 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 44%">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B5">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Net IGI product sales </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.2"> 1,377 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.4"> 2,792 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.5" nowrap="nowrap">   </td> </tr> </table> Accounts receivable are presented net of SRA balances of $0.8 million and $0 at June 30, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.4 million and $0 at June 30, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.2 million and $0 for the three month periods ended June 30, 2013 and 2012, respectively, were included in cost of goods sold. Wholesale fees of $0.4 million and $0 for the six month periods ended June 30 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with the three products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.5 million and $0 at June 30, 2013 and 2012, respectively, related to these royalties. Royalty expense of $0.5 million and $0 was included in cost of goods sold for the three months ended June 30, 2013 and 2012, respectively. Royalty expense of $1 million and $0 was included in cost of goods sold for year to date as of June 30 for 2013, and 2012 respectively. Product Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products. Sales of the IGI labeled products are recognized when received by the customer. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs. Research and Development Income:  The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.   In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.

0.90 0.95

800000

400000

200000 0 400000 0

500000

1000000

Major Customers Major customers of the Company are defined as having revenue greater than 10% of total gross revenue. For the three months ended June 30, 2013, three of the Company’s customers accounted for 41% of the Company’s revenue. For the three months ended June 30, 2012, five of the Company’s customers accounted for 74% of the Company’s revenue. Two of these customers are the same for both periods. For the six months ended June 30, 2013 and 2012, five of the Company’s customers accounted for 67% and three of the Company’s customers accounted for 64% of the Company’s revenue, respectively. Two of these customers are the same for both periods. Accounts receivable related to the Company’s major customers comprised 67% of all accounts receivable as of June 30, 2013. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations.

0.10

3 0.41 5 0.74 5 0.67 3 0.64 0.67

Recent Accounting Pronouncements There were no new accounting pronouncements for the three months ended June 30, 2013 that have a material impact on the Company’s consolidated financial statements.

<table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL998" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 44%; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid"> Gross-To-Net Sales Deductions </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.amt.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BORDER-TOP: #000000 1px solid" id="TBL998.finRow.1.trail.B5">   </td> </tr> <tr> <td style="WIDTH: 44%">   </td> <td id="TBL998.finRow.2.lead.B2">   </td> <td id="TBL998.finRow.2.symb.B2">   </td> <td id="TBL998.finRow.2.amt.B2">   </td> <td id="TBL998.finRow.2.trail.B2">   </td> <td id="TBL998.finRow.2.lead.B3">   </td> <td id="TBL998.finRow.2.symb.B3">   </td> <td id="TBL998.finRow.2.amt.B3">   </td> <td id="TBL998.finRow.2.trail.B3">   </td> <td id="TBL998.finRow.2.lead.B4">   </td> <td id="TBL998.finRow.2.symb.B4">   </td> <td id="TBL998.finRow.2.amt.B4">   </td> <td id="TBL998.finRow.2.trail.B4">   </td> <td id="TBL998.finRow.2.lead.B5">   </td> <td id="TBL998.finRow.2.symb.B5">   </td> <td id="TBL998.finRow.2.amt.B5">   </td> <td id="TBL998.finRow.2.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: center; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.lead.D2">   </td> <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.3.amt.D2" colspan="6"> Three months ended June 30, </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.trail.B3">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.lead.D4">   </td> <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.3.amt.D4" colspan="6"> Six months ended June 30, </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.3.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: right; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D2">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D2" colspan="2"> 2013 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D2">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D3">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D3" colspan="2"> 2012 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D3">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D4">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D4" colspan="2"> 2013 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D4">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.lead.D5">   </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.4.amt.D5" colspan="2"> 2012 </td> <td style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL998.finRow.4.trail.D5">   </td> </tr> <tr> <td style="WIDTH: 44%">   </td> <td id="TBL998.finRow.5.lead.B2">   </td> <td id="TBL998.finRow.5.symb.B2">   </td> <td id="TBL998.finRow.5.amt.B2">   </td> <td id="TBL998.finRow.5.trail.B2">   </td> <td id="TBL998.finRow.5.lead.B3">   </td> <td id="TBL998.finRow.5.symb.B3">   </td> <td id="TBL998.finRow.5.amt.B3">   </td> <td id="TBL998.finRow.5.trail.B3">   </td> <td id="TBL998.finRow.5.lead.B4">   </td> <td id="TBL998.finRow.5.symb.B4">   </td> <td id="TBL998.finRow.5.amt.B4">   </td> <td id="TBL998.finRow.5.trail.B4">   </td> <td id="TBL998.finRow.5.lead.B5">   </td> <td id="TBL998.finRow.5.symb.B5">   </td> <td id="TBL998.finRow.5.amt.B5">   </td> <td id="TBL998.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Gross IGI product sales </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.2"> 2,114 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.4"> 4,380 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.6.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Chargebacks </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.2"> 562 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.4"> 1,222 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Sales discounts and other allowances </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.2"> 175 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.4"> 365 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.8.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Gross to net adjustments </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.2"> 737 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.4"> 1,588 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.9.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 44%">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.amt.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff" id="TBL998.finRow.10.trail.B5">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 44%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Net IGI product sales </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.2"> 1,377 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.2" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.3"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.4"> 2,792 </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.4" nowrap="nowrap">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 11%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.amt.5"> - </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL998.finRow.11.trail.5" nowrap="nowrap">   </td> </tr> </table>

2114

4380

562 1222

175

365

737 1588

1377

2792

4.      Inventories Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. Inventories at June 30, 2013 and December 31, 2012 consist of: <table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 10%" id="TBL585" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: left; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2"> June 30, 2013 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.3"> December 31, 2012 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2-0">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2-0">   </td> <td style="TEXT-ALIGN: center; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2-0">  (Audited) </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.2-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.3-0">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.3-0">   </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.3-0"> (Unaudited) </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3-0" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2-1">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2-1">   </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2-1" colspan="5"> (amounts in thousands) </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3-1" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Raw materials </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2-2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2-2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2-2"> 1,904 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.2-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.3-1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.3-1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.3-1"> 1,673 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3-2" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Work in progress </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.amt.2"> 85 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.amt.3"> 26 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.trail.3" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Finished goods </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.amt.2"> 115 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.amt.3"> 74 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.trail.3" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Total </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.amt.2"> 2,104 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.symb.3"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.amt.3"> 1,773 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.trail.3" nowrap="nowrap">   </td> </tr> </table>

<table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 10%" id="TBL585" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: left; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2"> June 30, 2013 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.3"> December 31, 2012 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2-0">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2-0">   </td> <td style="TEXT-ALIGN: center; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2-0">  (Audited) </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.2-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.3-0">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.3-0">   </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.3-0"> (Unaudited) </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3-0" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2-1">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2-1">   </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2-1" colspan="5"> (amounts in thousands) </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3-1" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Raw materials </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.2-2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.2-2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.2-2"> 1,904 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.2-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.lead.3-1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.symb.3-1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.amt.3-1"> 1,673 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.4.trail.3-2" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Work in progress </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.amt.2"> 85 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.amt.3"> 26 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.5.trail.3" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Finished goods </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.amt.2"> 115 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.amt.3"> 74 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.6.trail.3" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; WIDTH: 66%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Total </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.symb.2"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.amt.2"> 2,104 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.symb.3"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.amt.3"> 1,773 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL585.finRow.7.trail.3" nowrap="nowrap">   </td> </tr> </table>

1904000

1673000

85000

26000

115000

74000

5.      Stock-Based Compensation Under the 1998 Directors Stock Plan, as amended, 600,000 shares of the Company’s common stock are authorized under the plan and reserved for issuance to non-employee directors, in lieu of payment of directors’ fees in cash. In November 2009, the Company’s Board of Directors approved the elimination of payment of directors’ fees in stock under this plan beginning in the fourth quarter of 2009. The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. An aggregate of 1,975,000 shares have been approved and authorized for issuance pursuant to this plan. A total of 2,179,798 options have been granted to non-employee directors through June 30, 2013 and 727,782 of those have been forfeited through June 30, 2013 and returned to the option pool. The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years.  The 1999 Stock Incentive Plan, as amended (the “1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company's employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years, has been granted at 100% of the fair market value of the Company's common stock at the time of grant. Options outstanding under the 1999 Plan are generally exercisable in cumulative increments over four years commencing one year from the date of grant.  On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by partial written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company’s current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of common stock available for grant under such plan by adding 2,000,000 shares of common stock. The 2009 Plan, as amended on May 19, 2010, authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of June 30, 2013, options to purchase 1,858,000 shares of common stock were outstanding under the 2009 Plan and 1,148,748 shares of restricted stock had been granted under the 2009 Plan, 230,420 of those have been forfeited through June 30, 2013 and returned to the pool.  Stock Options The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. The interest rates used are the U.S. Treasury yield curve in effect at the time of the grant.   <table style="TEXT-INDENT: 0px; WIDTH: 80%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 20%" id="TBL626" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL626.finRow.1"> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL626.finRow.1.lead.D2" width="15">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL626.finRow.1.amt.D2" width="213" colspan="3"> For the three months ended June 30, 2013 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL626.finRow.1.trail.D2" width="15">   </td> </tr> <tr id="TBL626.finRow.2"> <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Expected volatility </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.lead.2" width="15">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.symb.2" width="90">  37.5% </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2" width="41"> – </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2-0" width="82"> 38.3% </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.trail.2" width="15" nowrap="nowrap">   </td> </tr> <tr id="TBL626.finRow.2-0"> <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Expected term (in years) </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.lead.2-0" width="15">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.symb.2-0" width="90"> 3.2 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2-1" width="41"> – </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2-2" width="82"> 3.3 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.trail.2-0" width="15" nowrap="nowrap">   </td> </tr> <tr id="TBL626.finRow.4"> <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Risk-free rate </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.lead.2" width="15">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.symb.2" width="90">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.amt.2" width="41"> 0.43% </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.amt.2-0" width="82">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.trail.2" width="15" nowrap="nowrap">   </td> </tr> <tr id="TBL626.finRow.5"> <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Expected dividends </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.lead.2" width="15">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.symb.2" width="90">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.amt.2" width="41"> 0% </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.amt.2-0" width="82">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.trail.2" width="15" nowrap="nowrap">   </td> </tr> </table> A summary of option activity under the 1999 Plan, the Director Plan and the 2009 Plan as of June 30, 2013 and changes during the period are presented below: <table style="TEXT-INDENT: 0px; WIDTH: 80%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 20%" id="TBL667" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL667.finRow.2"> <td style="TEXT-ALIGN: center; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.amt.D2" colspan="2"> Number of Options </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.trail.D2">   </td> <td style="TEXT-ALIGN: left; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.amt.D3" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.trail.D3">   </td> </tr> <tr id="TBL667.finRow.3"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Outstanding as of January 1, 2013 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.amt.2"> 2,606,500 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.amt.3"> 1.10 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.4"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Issued </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.amt.2"> 166,500 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.amt.3"> 1.12 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.5"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Exercised </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.amt.2"> (118,670 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.trail.2" nowrap="nowrap"> ) </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.amt.3"> 1.08 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.6"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Forfeited </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.amt.2"> (72,330 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.trail.2" nowrap="nowrap"> ) </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.amt.3"> 1.33 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.7"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Expired </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.amt.2"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.8"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Outstanding as of June 30, 2013 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.amt.2"> 2,582,000 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.symb.3"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.amt.3"> 1.09 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.9"> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 62%">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.lead.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.symb.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.amt.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.trail.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.lead.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.symb.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.amt.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.trail.B3">   </td> </tr> <tr id="TBL667.finRow.10"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Exercisable as of June 30, 2013 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.amt.2"> 1,034,165 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.amt.3"> 1.17 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.trail.3" nowrap="nowrap">   </td> </tr> </table> Based upon application of the Black-Scholes option-pricing formula described above, the weighted-average grant-date fair value of options granted during the six months ended June 30, 2013 was $0.31.  The following table summarizes information regarding options outstanding and exercisable at June 30, 2013: <table style="TEXT-INDENT: 0px; WIDTH: 95%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL732S1" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.1" colspan="2"> Outstanding: </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.2">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.2">   </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.2">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.3">   </td> <td style="TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.4">   </td> <td style="TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.B5">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.B5">   </td> <td style="TEXT-ALIGN: center; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.B5">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.B5">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.1-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.1" colspan="5"> Range of Exercise Prices </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.2-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.3-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.3-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.3-0"> Stock Options Outstanding </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.3-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.4-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.4-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.4-0"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.4-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.B5-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.B5-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.B5-0"> Weighted Average Remaining Contractual Life </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.B5-0">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.1-1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.1-0"> 0.55 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.1-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.2-0">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.2-0"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.2-0"> 1.00 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.2-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.3-1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.3-1">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.3-1"> 218,000 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.3-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.4-1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.4-1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.4-1"> 0.76 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.4-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.B5-1">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.B5-1">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.B5-1">  5.33 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.B5-1">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.1"> 1.01 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.2"> 1.50 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.3"> 2,203,000 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.4"> 1.09 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.B5">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.B5">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.B5">  8.40 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.1"> 1.51 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.2"> 1.68 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.3"> 161,000 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.4"> 1.67 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.B5">  7.66 </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.B5">   </td> </tr> <tr> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.D1" colspan="2"> Total </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.D1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.B2">   </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.3"> 2,582,000 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.4"> 1.09 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.5"> 8.10 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> </table> <table style="TEXT-INDENT: 0px; WIDTH: 80%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 20%" id="TBL1030" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL1030.finRow.1"> <td style="WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.amt.D2" colspan="6"> Exercisable: </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.trail.D2">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.lead.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.symb.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.amt.B3">   </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.trail.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.lead.B4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.symb.B4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.amt.B4">   </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.trail.B4">   </td> </tr> <tr id="TBL1030.finRow.3"> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.amt.D2" colspan="6"> Range of Exercise Prices </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.trail.D2">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.amt.D3" colspan="2"> Stock Options Exercisable </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.trail.D3">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.lead.D4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.amt.D4" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.trail.D4">   </td> </tr> <tr id="TBL1030.finRow.4"> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B1">   </td> <td style="WIDTH: 6%" id="TBL1030.finRow.4.amt.B1">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B1">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.lead.B2">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B2">   </td> <td style="WIDTH: 6%" id="TBL1030.finRow.4.amt.B2">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B2">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.lead.B3">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B3">   </td> <td style="WIDTH: 12%" id="TBL1030.finRow.4.amt.B3">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B3">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.lead.B4">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B4">   </td> <td style="WIDTH: 12%" id="TBL1030.finRow.4.amt.B4">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B4">   </td> </tr> <tr id="TBL1030.finRow.5"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.1"> 0.55 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.2"> 1.00 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.3"> 212,000 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.4"> 0.75 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.4" nowrap="nowrap">   </td> </tr> <tr id="TBL1030.finRow.6"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.1"> 1.01 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.2"> 1.50 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.3"> 672,165 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.4"> 1.19 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.4" nowrap="nowrap">   </td> </tr> <tr id="TBL1030.finRow.7"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.1"> 1.51 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.2"> 1.68 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.3"> 150,000 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.4"> 1.67 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.4" nowrap="nowrap">   </td> </tr> <tr id="TBL1030.finRow.8"> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.D1" colspan="2"> Total </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.D1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.lead.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.symb.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.B2">   </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.3"> 1,034,165 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.4"> 1.17 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.4" nowrap="nowrap">   </td> </tr> </table> As of June 30, 2013, the intrinsic value of the options outstanding is $904,790 and the intrinsic value of the options exercisable is $302,585. The total intrinsic value of the options exercised during the six months ended June 30, 2013 was $41,654. As of June 30, 2013, there was approximately $345,000 of total unrecognized compensation cost that will be recognized through May 2016 related to non-vested share-based compensation arrangements granted under the equity plans. Restricted Stock The Company periodically grants restricted stock awards to certain officers and other employees that typically vest one to three years from their grant date. The Company recognized $4,900 and $56,500 of compensation expense during the three months ended June 30, 2013 and 2012, respectively, related to restricted stock awards.  Stock compensation expense is recognized over the vesting period of the restricted stock.  At June 30, 2013, the Company had approximately $11,400 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized from July 2013 through January 2014. <table style="TEXT-INDENT: 0px; WIDTH: 85%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 7.5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 7.5%" id="TBL763" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL763.finRow.1"> <td style="TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.amt.D2" colspan="2"> Number of Restricted Stock </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.trail.D2">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.amt.D3" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.trail.D3">   </td> </tr> <tr id="TBL763.finRow.2"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Non-vested balance at January 1, 2013 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.amt.2"> 29,334 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.amt.3"> 1.00 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.3"> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 70%">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.lead.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.symb.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL763.finRow.3.amt.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.trail.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.lead.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.symb.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL763.finRow.3.amt.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.trail.B3">   </td> </tr> <tr id="TBL763.finRow.4"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Changes during the period: </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.lead.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.symb.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.amt.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.trail.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.lead.B3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.symb.B3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.amt.B3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.trail.B3">   </td> </tr> <tr id="TBL763.finRow.5"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Shares granted </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.6"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Shares vested </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.7"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Shares forfeited </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.amt.2"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.8"> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 70%">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.lead.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.symb.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 12%" id="TBL763.finRow.8.amt.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.trail.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.lead.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.symb.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 12%" id="TBL763.finRow.8.amt.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.trail.B3">   </td> </tr> <tr id="TBL763.finRow.9"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Non-vested balance at June 30, 2013 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.amt.2"> 29,334 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.symb.3"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.amt.3"> 1.00 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.trail.3" nowrap="nowrap">   </td> </tr> </table>

600000

1975000

2179798

-727782

one

P10Y

3200000

2892500

P10Y 1.00

P4Y

2000000

4000000

1000000

1858000

1148748

230420

0.31

904790

302585

41654

345000

P1Y

P3Y

4900

56500

11400

<table style="TEXT-INDENT: 0px; WIDTH: 80%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 20%" id="TBL626" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL626.finRow.1"> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL626.finRow.1.lead.D2" width="15">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL626.finRow.1.amt.D2" width="213" colspan="3"> For the three months ended June 30, 2013 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL626.finRow.1.trail.D2" width="15">   </td> </tr> <tr id="TBL626.finRow.2"> <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Expected volatility </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.lead.2" width="15">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.symb.2" width="90">  37.5% </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2" width="41"> – </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2-0" width="82"> 38.3% </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.trail.2" width="15" nowrap="nowrap">   </td> </tr> <tr id="TBL626.finRow.2-0"> <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Expected term (in years) </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.lead.2-0" width="15">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.symb.2-0" width="90"> 3.2 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2-1" width="41"> – </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.amt.2-2" width="82"> 3.3 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.2.trail.2-0" width="15" nowrap="nowrap">   </td> </tr> <tr id="TBL626.finRow.4"> <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Risk-free rate </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.lead.2" width="15">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.symb.2" width="90">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.amt.2" width="41"> 0.43% </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.amt.2-0" width="82">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.4.trail.2" width="15" nowrap="nowrap">   </td> </tr> <tr id="TBL626.finRow.5"> <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" width="1246"> Expected dividends </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.lead.2" width="15">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.symb.2" width="90">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.amt.2" width="41"> 0% </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.amt.2-0" width="82">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL626.finRow.5.trail.2" width="15" nowrap="nowrap">   </td> </tr> </table>

0.375

0.383

P3Y73D

P3Y109D

0.0043

0.00

<table style="TEXT-INDENT: 0px; WIDTH: 80%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 20%" id="TBL667" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL667.finRow.2"> <td style="TEXT-ALIGN: center; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">   </td> <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.amt.D2" colspan="2"> Number of Options </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.trail.D2">   </td> <td style="TEXT-ALIGN: left; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.amt.D3" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.2.trail.D3">   </td> </tr> <tr id="TBL667.finRow.3"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Outstanding as of January 1, 2013 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.amt.2"> 2,606,500 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.amt.3"> 1.10 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.3.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.4"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Issued </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.amt.2"> 166,500 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.amt.3"> 1.12 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.4.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.5"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Exercised </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.amt.2"> (118,670 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.trail.2" nowrap="nowrap"> ) </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.amt.3"> 1.08 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.5.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.6"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Forfeited </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.amt.2"> (72,330 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.trail.2" nowrap="nowrap"> ) </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.amt.3"> 1.33 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.6.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.7"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Expired </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.amt.2"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.7.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.8"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Outstanding as of June 30, 2013 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.amt.2"> 2,582,000 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.symb.3"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.amt.3"> 1.09 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.8.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL667.finRow.9"> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 62%">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.lead.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.symb.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.amt.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.trail.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.lead.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.symb.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.amt.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff" id="TBL667.finRow.9.trail.B3">   </td> </tr> <tr id="TBL667.finRow.10"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 62%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom"> Exercisable as of June 30, 2013 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.amt.2"> 1,034,165 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.amt.3"> 1.17 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL667.finRow.10.trail.3" nowrap="nowrap">   </td> </tr> </table>

2606500

1.10

166500

1.12

118670

1.08

72330

1.33

2582000

1.09

1034165

1.17

<table style="TEXT-INDENT: 0px; WIDTH: 95%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL732S1" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.1" colspan="2"> Outstanding: </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.2">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.2">   </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.2">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.3">   </td> <td style="TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.4">   </td> <td style="TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.B5">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.B5">   </td> <td style="TEXT-ALIGN: center; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.B5">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.B5">   </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.1-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.1" colspan="5"> Range of Exercise Prices </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.2-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.3-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.3-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.3-0"> Stock Options Outstanding </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.3-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.4-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.4-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.4-0"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.4-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.B5-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.B5-0">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.B5-0"> Weighted Average Remaining Contractual Life </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.B5-0">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.1-1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.1-0"> 0.55 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.1-0" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.2-0">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.2-0"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.2-0"> 1.00 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.2-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.3-1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.3-1">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.3-1"> 218,000 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.3-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.4-1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.4-1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.4-1"> 0.76 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.4-1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.lead.B5-1">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.symb.B5-1">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.amt.B5-1">  5.33 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.4.trail.B5-1">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.1"> 1.01 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.2"> 1.50 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.3"> 2,203,000 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.4"> 1.09 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.lead.B5">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.symb.B5">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.amt.B5">  8.40 </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.1"> 1.51 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.2"> 1.68 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.3"> 161,000 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.4"> 1.67 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.lead.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.symb.B5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.amt.B5">  7.66 </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.6.trail.B5">   </td> </tr> <tr> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.D1" colspan="2"> Total </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.D1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.B2">   </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.3"> 2,582,000 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.4"> 1.09 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.lead.5">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.symb.5">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 19%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.amt.5"> 8.10 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 2%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL732.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> </table>

0.55

1.00

218000

0.76

P5Y120D

1.01

1.50

2203000

1.09

P8Y146D

1.51

1.68

161000

1.67

P7Y240D

2582000

1.09

P8Y36D

<table style="TEXT-INDENT: 0px; WIDTH: 80%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 20%" id="TBL1030" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL1030.finRow.1"> <td style="WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.amt.D2" colspan="6"> Exercisable: </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.trail.D2">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.lead.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.symb.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.amt.B3">   </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.trail.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.lead.B4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.symb.B4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.amt.B4">   </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.1.trail.B4">   </td> </tr> <tr id="TBL1030.finRow.3"> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 10%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.amt.D2" colspan="6"> Range of Exercise Prices </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.trail.D2">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.amt.D3" colspan="2"> Stock Options Exercisable </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.trail.D3">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.lead.D4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.amt.D4" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.3.trail.D4">   </td> </tr> <tr id="TBL1030.finRow.4"> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B1">   </td> <td style="WIDTH: 6%" id="TBL1030.finRow.4.amt.B1">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B1">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.lead.B2">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B2">   </td> <td style="WIDTH: 6%" id="TBL1030.finRow.4.amt.B2">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B2">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.lead.B3">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B3">   </td> <td style="WIDTH: 12%" id="TBL1030.finRow.4.amt.B3">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B3">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.lead.B4">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.symb.B4">   </td> <td style="WIDTH: 12%" id="TBL1030.finRow.4.amt.B4">   </td> <td style="WIDTH: 1%" id="TBL1030.finRow.4.trail.B4">   </td> </tr> <tr id="TBL1030.finRow.5"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.1"> 0.55 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.2"> 1.00 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.3"> 212,000 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.amt.4"> 0.75 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.5.trail.4" nowrap="nowrap">   </td> </tr> <tr id="TBL1030.finRow.6"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.1"> 1.01 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.2"> 1.50 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.3"> 672,165 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.symb.4"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.amt.4"> 1.19 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.6.trail.4" nowrap="nowrap">   </td> </tr> <tr id="TBL1030.finRow.7"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.1"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.1"> 1.51 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.1" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.2"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.2"> 1.68 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.3"> 150,000 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.amt.4"> 1.67 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.7.trail.4" nowrap="nowrap">   </td> </tr> <tr id="TBL1030.finRow.8"> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.D1" colspan="2"> Total </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.D1">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.lead.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.symb.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.B2">   </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.3"> 1,034,165 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.symb.4"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 22.5pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.amt.4"> 1.17 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1030.finRow.8.trail.4" nowrap="nowrap">   </td> </tr> </table>

0.55

1.00

212000

0.75

1.01

1.50

672165

1.19

1.51

1.68

150000

1.67

1034165

1.17

<table style="TEXT-INDENT: 0px; WIDTH: 85%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 7.5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 7.5%" id="TBL763" border="0" cellspacing="0" cellpadding="0"> <tr id="TBL763.finRow.1"> <td style="TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.amt.D2" colspan="2"> Number of Restricted Stock </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.trail.D2">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.amt.D3" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.1.trail.D3">   </td> </tr> <tr id="TBL763.finRow.2"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Non-vested balance at January 1, 2013 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.amt.2"> 29,334 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.amt.3"> 1.00 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.2.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.3"> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 70%">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.lead.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.symb.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL763.finRow.3.amt.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.trail.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.lead.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.symb.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL763.finRow.3.amt.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL763.finRow.3.trail.B3">   </td> </tr> <tr id="TBL763.finRow.4"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Changes during the period: </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.lead.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.symb.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.amt.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.trail.B2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.lead.B3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.symb.B3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.amt.B3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle" id="TBL763.finRow.4.trail.B3">   </td> </tr> <tr id="TBL763.finRow.5"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Shares granted </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.5.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.6"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Shares vested </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.6.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.7"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Shares forfeited </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.amt.2"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.symb.3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.7.trail.3" nowrap="nowrap">   </td> </tr> <tr id="TBL763.finRow.8"> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 70%">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.lead.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.symb.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 12%" id="TBL763.finRow.8.amt.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.trail.B2">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.lead.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.symb.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 12%" id="TBL763.finRow.8.amt.B3">   </td> <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%" id="TBL763.finRow.8.trail.B3">   </td> </tr> <tr id="TBL763.finRow.9"> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle"> Non-vested balance at June 30, 2013 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.amt.2"> 29,334 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.lead.3">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.symb.3"> $ </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.amt.3"> 1.00 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL763.finRow.9.trail.3" nowrap="nowrap">   </td> </tr> </table>

29334

1.00

29334

1.00

6.      Income Taxes As a result of the Company’s history of continuing tax losses, the Company does not have a current tax provision and has recorded a full valuation allowance against its net deferred tax asset. The Company has not recorded a liability for unrecognized tax benefits at June 30, 2013 and no significant changes are expected in the next twelve months. The tax years 2009-2012 remain open to examination by the major taxing jurisdictions to which the Company is subject.          There was no accrued interest related to unrecognized tax benefits at June 30, 2013. The Company’s ability to use net operating loss carry forwards may be subject to substantial limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2009 and 2010, as well as the possibility of such limitation having any material effect on the application of net operating loss carry forwards in the immediate future. The Company believes that it is likely that a change in ownership took place and that the net operating loss carry forwards will be limited.

0.50

0.05

7.      License Fee  On December 12, 2005, the Company extended its license agreement for an additional ten years with Novavax, Inc. for $1,000,000. This extension entitles the Company to exclusively use of the Novasome® lipid vesicle encapsulation and certain other technologies in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals, and the processes for making the same through 2015. This payment is being amortized ratably over the ten-year period. The Company recorded amortization expense of $25,000 related to this agreement for each of the three month periods ended June 30, 2013 and 2012 and amortization expense of $50,000 related to this agreement for each of the six months ended June 30, 2013 and 2012.

P10Y

1000000

25000

50000

8.      Note Payable - Bank On August 31, 2012, IGI Laboratories, Inc. and its subsidiaries, Igen, Inc. and IGI Labs, Inc., entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Square 1 Bank (the “Lender”) pursuant to which the Lender agreed to extend credit facilities to the Company (the “Financing”). The Company drew down $1,000,000 in principal amount on August 31, 2012 and $1,000,000 in principal amount on February 5, 2013. To secure payment of the amounts financed under the Loan and Security Agreement, the Company has granted to the Lender a continuing security interest in and against, generally, all of its tangible and intangible assets, except intellectual property. Under the Loan and Security Agreement, the Company can request revolving loan advances under (a) the Formula Revolving Line and (b) the Non-Formula Revolving Line, and term loan advances under the term loans. The aggregate total borrowings under the facilities cannot exceed the total borrowing limit of $3,000,000 at any one time outstanding. Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 1.9% above the prime rate then in effect, and (B) 5.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.15% above the prime rate then in effect, and (B) 5.9%. Term loan advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.4% above the prime rate then in effect, and (B) the rate in effect at December 31, 2012, which was 6.15%. The term of the Formula Revolving Line and the Non-Formula Revolving Line is one year from the date of the Loan and Security Agreement and can be extended by mutual agreement of the parties. The term of the term loans is 42 months from the date of the Loan and Security Agreement, but term loan advances are available to the Company only until February 28, 2014. In accordance with the Loan and Security Agreement, the Company must maintain a liquidity ratio of at least 1.25 to 1.00 (the “LQR Threshold”), provided that the LQR Threshold shall be reduced to 1.00 to 1.00 so long as the Company has achieved minimum Revenue, measured monthly on a trailing three month basis, of at least the amounts listed in the document for the corresponding reporting periods. To further clarify, if at any time the Company is not in compliance with the minimum revenue amounts set forth below, the LQR Threshold shall be increased to 1.25 to 1.00. “Liquidity” means the sum of: (i) unrestricted cash in bank plus (ii) the Borrowing Base (the amount drawn to date). In accordance with the Loan and Security Agreement, liquidity ratio means the ratio of Liquidity to all Indebtedness to the Lender (but excluding any Indebtedness to the Lender which is secured by cash held in a segregated deposit account at the Lender). As of June 30, 2013, the Company was in compliance with the LQR Threshold required under the Loan and Security Agreement. In connection with the Financing, the Company paid in full its existing credit facility with Amzak Capital Management, LLC (see Note 9 below) and executed a Release and Termination Note and Credit Agreement with Amzak Capital Management, LLC to release the Company from any future obligations under the Credit Agreement executed on December 21, 2010 (the “Amzak Credit Facility ”). On August 2, 2013, the Company entered into an Amendment to the Loan and Security Agreement (the “Amendment”). In accordance with the Amendment, notwithstanding the existing LQR Thresholds, for so long as the Company is in compliance with the minimum revenue requirements established in this Amendment, the Company shall be permitted to maintain a liquidity ratio of not less than .90 to 1.00 for a continuous 60 day period every 12 months. In connection with the lower liquidity ratio, in accordance with the Amendment, under the Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 4.9% above the prime rate then in effect, and (B) 8.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 5.15% above the prime rate then in effect, and (B) 8.9%, until such time that the lower liquidity ratio is no longer in place. If the Company remains in compliance through the end of December of 2013, the aggregate borrowing amount will be increased from $3,000,000 to $5,000,000. On August 2, 2013, the Company drew down an additional $1,000,000 from the available credit facility.

1000000

0.019

0.0565

0.0215

0.059

0.024

0.0615

1.25 1.00 1.00

0.049

0.0865

0.0515

0.089

5000000

1000000

9.      Stock Warrants Stock Warrants activity for the quarters ended June 30, 2013 and 2012 consisted of: <table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL843" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: left; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.amt.D2" colspan="6"> 2013 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.trail.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.lead.D4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.amt.D4" colspan="6"> 2012 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: center; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D2" colspan="2"> Warrants </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D2">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D3" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D4" colspan="2"> Warrants </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D5" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D5">   </td> </tr> <tr> <td style="WIDTH: 40%">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B2">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B2">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B2">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B2">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B3">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B3">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B3">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B3">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B4">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B4">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B4">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B4">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B5">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B5">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B5">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Beginning balance </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.2"> 782,259 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.3"> 0.85 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.4"> 1,235,877 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.5"> 0.35 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Stock warrants granted </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.4"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Stock warrants expired </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.4"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Stock warrants exercised </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.2"> (427,713 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.2" nowrap="nowrap"> ) </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.3"> 0.55 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.4"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.5"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Ending balance </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.2"> 354,546 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.3"> 1.21 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.4"> 1,235,877 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.5"> 0.35 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.5" nowrap="nowrap">   </td> </tr> </table> In connection with the private placement of the Company’s Common Stock on December 8, 2010, the Company granted common stock warrants to purchase 338,182 and 16,364 shares, respectively, to each of its two placement agents for $1.21 per share which expire on December 8, 2015. In connection with the private placement of the Company’s common stock in 2012, the Company granted common stock warrants to purchase 387,201 shares for $0.01 per share, which expire December 2022.  In addition, the Company executed as of December 31, 2012 a settlement agreement with Amzak Capital Management, LLC (“Amzak”) in connection with a common stock purchase warrant issued to Amzak on December 21, 2012 under which the Company issued a ten-year warrant to purchase up to 427,713 shares of the Company’s common stock, with an exercise price of $0.55 per share. The warrants were exercised in full on February 8, 2013. The amount of the fair value of the warrant issued was $209,000, and included as interest expense in 2012, as it related to the credit agreement which was terminated in August of 2012.

338182

16364

1.21

387201

0.01

P10Y

427713

0.55

209000

<table style="TEXT-INDENT: 0px; WIDTH: 90%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" id="TBL843" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: left; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.amt.D2" colspan="6"> 2013 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.trail.B3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.lead.D4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 16%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.amt.D4" colspan="6"> 2012 </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.1.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: center; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D2" colspan="2"> Warrants </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D2">   </td> <td style="TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D3">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D3" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D3">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D4" colspan="2"> Warrants </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D4">   </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.lead.D5">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.2.amt.D5" colspan="2"> Weighted Average Exercise Price </td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL843.finRow.2.trail.D5">   </td> </tr> <tr> <td style="WIDTH: 40%">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B2">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B2">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B2">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B2">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B3">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B3">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B3">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B3">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B4">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B4">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B4">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B4">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.lead.B5">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.symb.B5">   </td> <td style="WIDTH: 12%" id="TBL843.finRow.3.amt.B5">   </td> <td style="WIDTH: 1%" id="TBL843.finRow.3.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Beginning balance </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.2"> 782,259 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.3"> 0.85 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.4"> 1,235,877 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.amt.5"> 0.35 </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.4.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.lead.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.symb.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.5.amt.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.5.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Stock warrants granted </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.4"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.6.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Stock warrants expired </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.2">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.2">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.2"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.3"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.4">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.4">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.4"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.amt.5"> - </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.7.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Stock warrants exercised </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.2"> (427,713 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.2" nowrap="nowrap"> ) </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.3">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.3"> 0.55 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.4"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.symb.5">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.amt.5"> - </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.8.trail.5" nowrap="nowrap">   </td> </tr> <tr> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B2">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B3">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B4">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.lead.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.symb.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 12%" id="TBL843.finRow.9.amt.B5">   </td> <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%" id="TBL843.finRow.9.trail.B5">   </td> </tr> <tr> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top"> Ending balance </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.2">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.2"> 354,546 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.2" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.3">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.3"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.3"> 1.21 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.3" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.4">   </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.4"> 1,235,877 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.4" nowrap="nowrap">   </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.lead.5">   </td> <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.symb.5"> $ </td> <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.amt.5"> 0.35 </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL843.finRow.10.trail.5" nowrap="nowrap">   </td> </tr> </table>

782259

0.85

1235877

0.35

0 0 0 0 0 0 0 0 427713 0.55

354546

1.21

1235877

0.35

10.    Asset Purchase Agreement On February 1, 2013, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Prasco, LLC, an Ohio limited liability company (“Prasco”), pursuant to which the Company purchased from Prasco assets associated with econazole nitrate cream 1% (the “Product”), which is available in 15g, 30g, and 85g tubes has United States Food and Drug Administration approved indications for the treatment of tinea pedis, tinea cruris, and tinea corporis as well as the treatment of cutaneous candidiasis and tinea versicolor. In consideration for the purchase of the assets pursuant to the Purchase Agreement, the Company paid Prasco $1.4 million in cash and will be required to pay an additional aggregate of $400,000 upon the occurrence of certain milestone events (the “Milestone Payment”). The Milestone Payment is secured by a first-priority security interest in the acquired assets under the Purchase Agreement. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment and related costs to acquire the asset are included as part of product acquisition costs totaling $1.4 million.  Upon the completion of the milestone payment, the Company will capitalize the remaining milestone payment and related acquisition costs and amortize the costs over fifteen years, the useful life of the acquired product and product rights. Under and subject to the terms and conditions of the Purchase Agreement, Prasco will continue to distribute the Product during a six-month period following the closing of the Purchase Agreement or for a shorter period if the Company has completed the technical transfer of the Product and begun manufacturing the Product under its own label. The Company expects sales of the product in the third quarter of 2013. In addition, the Purchase Agreement contains certain non-compete restrictions preventing Prasco from selling the Product in United States for a period of seven years.

1400000

400000

P15Y

seven

EX-101.SCH 7 ig-20130630.xsd 001 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Note 1 - Organization link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Note 2 - Liquidity link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Note 4 - Inventories link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Note 5 - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Note 6 - Income Taxes link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Note 7 - License Fee link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Note 8 - Note Payable - Bank link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Note 9 - Stock Warrants link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Note 10 - Asset Purchase Agreement link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Note 4 - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Note 5 - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Note 9 - Stock Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Note 1 - Organization (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Note 2 - Liquidity (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details) - Net revenues and accounts receivable balances iThe Company’s consolidated financial statements are presented net of SRA estimates link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Note 4 - Inventories (Details) - Inventories link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Note 5 - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Option Activity link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Options Outstanding and Exercisable link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Restricted Stock Awards link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Note 6 - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Note 7 - License Fee (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Note 8 - Note Payable - Bank (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Note 9 - Stock Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Note 9 - Stock Warrants (Details) - Stock Warrants Activity link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Note 10 - Asset Purchase Agreement (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ig-20130630_cal.xml EX-101.DEF 9 ig-20130630_def.xml EX-101.LAB 10 ig-20130630_lab.xml Income Statement [Abstract] Revenues: Revenues: [Abstract] Product sales, net Research and development income Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets and from the leasing or otherwise lending to a third party the entity's rights or title to certain property. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Other revenue recognized during the period Licensing, royalty and other income Total revenues Cost and expenses: Cost and expenses: [Abstract] Cost of sales Selling, general and administrative expenses Product development and research expenses Total costs and expenses Operating loss Interest expense and other, net Net loss Basic and diluted loss per share (in Dollars per share) Weighted Average of Common Stock and Common Stock Equivalents Outstanding Weighted Average of Common Stock and Common Stock Equivalents Outstanding [Abstract] Basic and diluted (in Shares) Statement of Financial Position [Abstract] Class of Stock [Domain] ASSETS ASSETS [Abstract] Current assets: Current assets: [Abstract] Cash and cash equivalents Accounts receivable, net Inventories Prepaid expenses and other receivables Total current assets Property, plant and equipment, net Product Acquisition Costs Product acquisition costs, net Restricted cash, long term License fee, net Debt issuance costs, net Other Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES AND STOCKHOLDERS’ EQUITY [Abstract] Current liabilities: Current liabilities: [Abstract] Accounts payable Accrued expenses Deferred income, current Capital lease obligation, current Total current liabilities Note payable, bank Deferred income, long term Capital lease obligation, long term Total liabilities Commitments and contingencies Stockholders’ equity: Stockholders’ equity: [Abstract] Convertible Preferred Stock Common stock Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders' equity Convertible Preferred stock liquidation preference (in Dollars per share) Statement of Cash Flows [Abstract] Cash flows from operating activities: Cash flows from operating activities: [Abstract] Net loss Reconciliation of net loss to net cash used in operating activities: Reconciliation of net loss to net cash used in operating activities: [Abstract] Depreciation Amortization of license fee Stock-based compensation expense Provision for write down of inventory Amortization of debt issuance costs Loss on abandonment of property Changes in operating assets and liabilities: Changes in operating assets and liabilities: [Abstract] Accounts receivable Inventories Prepaid expenses and other assets Accounts payable and accrued expenses Deferred income Net cash used in operating activities Cash flows from investing activities: Cash flows from investing activities: [Abstract] Capital expenditures Product acquisition costs Net cash used in investing activities Cash flows from financing activities: Cash flows from financing activities: [Abstract] Proceeds from note payable, bank Principal payments on capital lease obligation Proceeds from exercise of common stock options and warrants. Proceeds from exercise of common stock options and warrants Costs related to stock issuance Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow information: Supplemental cash flow information: [Abstract] Cash payments for interest Cash payment for taxes Non cash investing and financing transactions: Non cash investing and financing transactions: [Abstract] Equipment purchases financed through capital leases Statement of Stockholders' Equity [Abstract] Equity Component [Domain] Stockbasedcompensationexpense [Domain] Balance, December 31, 2012 (Audited) Balance, December 31, 2012 (Audited) (in Shares) Stock based compensation expense Stock warrants exercised Stock warrants exercised (in Shares) Stock options exercised Stock options exercised (in Shares) Costs related to stock issuance Balance, June 30, 2013 (Unaudited) Balance, June 30, 2013 (Unaudited) (in Shares) Disclosure Text Block [Abstract] Nature of Operations [Text Block] Policy Text Block [Abstract] Liquidity Disclosure [Policy Text Block] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Disclosure Text Block Supplement [Abstract] Commitments Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Asset Purchase Agreement Disclosure [Abstract] Asset Purchase Agreement Disclosure [Abstract] Disclosure of Asset Purchase Agreements Asset Purchase Agreement Disclosure [Text Block] Use of Estimates, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Major Customers, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Inventory, Current [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Schedule of Exercisable Options by Exercise Price Range [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Net revenues and accounts receivable balances iThe Company’s consolidated financial statements are presented net of SRA estimates Net revenues and accounts receivable balances iThe Company’s consolidated financial statements are presented net of SRA estimates [Abstract] Scenario, Unspecified [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts, Notes, Loans and Financing Receivable [Line Items] Gross IGI product sales Chargebacks for poduct sales Chargebacks Sales discounts and other allowances Gross To Net Adjustments Gross to net adjustments Net IGI product sales Inventories Inventories [Abstract] Raw materials Work in progress Finished goods Total Fair Value Assumptions of Option Awards Fair Value Assumptions of Option Awards [Abstract] Range [Domain] Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards [Table] Note 5 - Stock-Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items] Expected volatility Expected term (in years) Risk-free rate Expected dividends Option Activity Option Activity [Abstract] Outstanding as of January 1, 2013 Outstanding as of January 1, 2013 (in Dollars per share) Issued Issued (in Dollars per share) Exercised Exercised (in Dollars per share) Forfeited Forfeited (in Dollars per share) Outstanding as of June 30, 2013 Outstanding as of June 30, 2013 (in Dollars per share) Exercisable as of June 30, 2013 Exercisable as of June 30, 2013 (in Dollars per share) Options Outstanding and Exercisable Options Outstanding and Exercisable [Abstract] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Range of Exercise Prices - Lower Limit Range of Exercise Prices - Upper Limit Stock Options Outstanding (in Shares) Weighted Average Exercise Price Weighted Average Remaining Contractual Life Exercisable Options by Exercise Price Exercisable Options by Exercise Price [Abstract] Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Table] Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items] Range of Exercise Prices - Lower Limit Stock Options Exercisable (in Shares) Exercisable - Weighted Average Exercise Price Restricted Stock Awards Restricted Stock Awards [Abstract] Non-vested balance at January 1, 2013 EX-101.PRE 11 ig-20130630_pre.xml XML 12 R8.xml IDEA: Note 2 - Liquidity 2.4.0.8007 - Disclosure - Note 2 - Liquiditytruefalsefalse1false falsefalsec2_From1Jan2013To30Jun2013http://www.sec.gov/CIK0000352998duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policy Text Block [Abstract]2false 2us-gaap_LiquidityDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 2.      Liquidity The Company’s principal sources of liquidity are cash and cash equivalents of approximately $1,313,000 at June 30, 2013, the $1,000,000 available under the $3,000,000 credit facility detailed below and cash from operations. The Company sustained net losses of $660,000 and $1,323,000 for the six months ended June 30, 2013 and 2012, respectively, and had working capital of $3,587,000 at June 30, 2013. The Company’s business operations have been primarily funded over the past four years through private placements of its capital stock. The Company raised an aggregate of $2,000,000 through private placements of equity with accredited investors in 2012, $7,213,000 in 2010 and $5,304,000 in 2009 principally from private equity investors. The use of proceeds is intended for general working capital needs as well as the acquisition of econozale nitrate cream 1% which was purchased on February 1, 2013. The Company purchased a product and certain product rights which are expected to provide contribution to its gross profit in 2013 (See Note 10). In August 2012, the Company also entered into a $3,000,000 line of credit (See Note 8). In February 2013, the Company drew down an additional $1,000,000 from the available credit facility. As of June 30, 2013, the outstanding balance on the line of credit was $2,000,000. On August 2, 2013, the Company drew down an additional $1.0 million from the available credit facility. The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that its existing capital resources will be sufficient to support its current business plan and operations for at least the next twelve months. falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.No definition available.false0Liquidity Disclosure [Policy Text Block]falseNote 2 - LiquidityUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://igilabs.com/role/Note2Liquidity12 XML 13 R6.xml IDEA: Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) 2.4.0.8005 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)truefalsefalse1falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalsePreferred Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PreferredStockMemberus-gaap_StatementEquityComponentsAxisexplicitMembertruefalseStockbasedcompensationexpense [Domain]ig_StockbasedcompensationexpenseAxisig_StockbasedcompensationexpenseDomainig_StockbasedcompensationexpenseAxisexplicitMemberPreferred Stock [Member]Stockbasedcompensationexpense [Domain]sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalsePreferred Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PreferredStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$2falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalseConvertible Preferred Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertiblePreferredStockMemberus-gaap_StatementEquityComponentsAxisexplicitMembertruefalseStockbasedcompensationexpense [Domain]ig_StockbasedcompensationexpenseAxisig_StockbasedcompensationexpenseDomainig_StockbasedcompensationexpenseAxisexplicitMemberConvertible Preferred Stock [Member]Stockbasedcompensationexpense [Domain]sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseConvertible Preferred Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertiblePreferredStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$3falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalseCommon Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMembertruefalseStockbasedcompensationexpense [Domain]ig_StockbasedcompensationexpenseAxisig_StockbasedcompensationexpenseDomainig_StockbasedcompensationexpenseAxisexplicitMemberCommon Stock [Member]Stockbasedcompensationexpense [Domain]sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseCommon Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$4falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalseAdditional Paid-in Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberfalsefalseStock Options other than restricted stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldiig_StockOptionsotherthanrestrictedstockMemberig_StockbasedcompensationexpenseAxisexplicitMemberAdditional Paid-in Capital [Member]Stock Options other than restricted stock [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAdditional Paid-in Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberfalsefalseStock Options other than restricted stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldiig_StockOptionsotherthanrestrictedstockMemberig_StockbasedcompensationexpenseAxisexplicitMemberUSDUSD$5falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalseAdditional Paid-in Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberfalsefalseRestricted Stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RestrictedStockMemberig_StockbasedcompensationexpenseAxisexplicitMemberAdditional Paid-in Capital [Member]Restricted Stock [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAdditional Paid-in Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberfalsefalseRestricted Stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RestrictedStockMemberig_StockbasedcompensationexpenseAxisexplicitMemberUSDUSD$6falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalseAdditional Paid-in Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMembertruefalseStockbasedcompensationexpense [Domain]ig_StockbasedcompensationexpenseAxisig_StockbasedcompensationexpenseDomainig_StockbasedcompensationexpenseAxisexplicitMemberAdditional Paid-in Capital [Member]Stockbasedcompensationexpense [Domain]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAdditional Paid-in Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$7falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*falsefalseRetained Earnings [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMembertruefalseStockbasedcompensationexpense [Domain]ig_StockbasedcompensationexpenseAxisig_StockbasedcompensationexpenseDomainig_StockbasedcompensationexpenseAxisexplicitMemberRetained Earnings [Member]Stockbasedcompensationexpense [Domain]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseRetained Earnings [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$8falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*truefalseEquity Component [Domain]us-gaap_StatementEquityComponentsAxisus-gaap_EquityComponentDomainus-gaap_StatementEquityComponentsAxisexplicitMemberfalsefalseStock Options other than restricted stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldiig_StockOptionsotherthanrestrictedstockMemberig_StockbasedcompensationexpenseAxisexplicitMemberEquity Component [Domain]Stock Options other than restricted stock [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseStock Options other than restricted stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldiig_StockOptionsotherthanrestrictedstockMemberig_StockbasedcompensationexpenseAxisexplicitMemberUSDUSD$9falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*truefalseEquity Component [Domain]us-gaap_StatementEquityComponentsAxisus-gaap_EquityComponentDomainus-gaap_StatementEquityComponentsAxisexplicitMemberfalsefalseRestricted Stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RestrictedStockMemberig_StockbasedcompensationexpenseAxisexplicitMemberEquity Component [Domain]Restricted Stock [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseRestricted Stock [Member]ig_StockbasedcompensationexpenseAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RestrictedStockMemberig_StockbasedcompensationexpenseAxisexplicitMemberUSDUSD$10falseColumnus-gaap_StatementEquityComponentsAxisAxis*Columnig_StockbasedcompensationexpenseAxisAxis*ColumnunitUnit*truefalseEquity Component [Domain]us-gaap_StatementEquityComponentsAxisus-gaap_EquityComponentDomainus-gaap_StatementEquityComponentsAxisexplicitMembertruefalseStockbasedcompensationexpense [Domain]ig_StockbasedcompensationexpenseAxisig_StockbasedcompensationexpenseDomainig_StockbasedcompensationexpenseAxisexplicitMemberEquity Component [Domain]Stockbasedcompensationexpense [Domain]sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDfalsefalse$na0001-01-01T00:00:000001-01-01T00:00:00USDUSD$1falseRowperiodPeriod*RowprimaryElement*2false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Balance, December 31, 2012 (Audited)duration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse500000500000USD$falsetruefalse2truefalsefalse15170001517000USD$falsetruefalse3truefalsefalse446000446000USD$falsetruefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse4740900047409000USD$falsetruefalse7truefalsefalse-43445000-43445000USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse64270006427000[1]USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2012-12-31T00:00:000001-01-01T00:00:002Balance, December 31, 2012 (Audited) at Dec. 31, 20122falseRowperiodPeriod*RowprimaryElement*3false 4us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Balance, December 31, 2012 (Audited) (in Shares)duration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse5050falsefalsefalse2truefalsefalse15501550falsefalsefalse3truefalsefalse4270503242705032falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 falseinstant2012-12-31T00:00:000001-01-01T00:00:001Balance, December 31, 2012 (Audited) (in Shares) at Dec. 31, 20123falseRowperiodPeriod*RowprimaryElement*4false 4us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Stock based compensation expenseduration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse103000103000falsefalsefalse5truefalsefalse90009000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse103000103000falsefalsefalse9truefalsefalse90009000falsefalsefalse10truefalsefalse112000112000falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Stock based compensation expense4falseRowperiodPeriod*RowprimaryElement*5false 4us-gaap_ProceedsFromWarrantExercisesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabelxbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from holders exercising their stock warrants.No definition available.false2Stock warrants exercisedduration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_ProceedsFromWarrantExercisesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse50005000falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse231000231000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse236000236000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from holders exercising their stock warrants.No definition available.false2Stock warrants exercised5falseRowperiodPeriod*RowprimaryElement*6false 4us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabelxbrli:sharesItemTypesharesThe number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false1Stock warrants exercised (in Shares)duration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse427713427713falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false1Stock warrants exercised (in Shares)6falseRowperiodPeriod*RowprimaryElement*7false 4us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabelxbrli:monetaryItemTypemonetaryValue of stock issued as a result of the exercise of stock options.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock options exercisedduration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse10001000falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse127000127000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse128000128000falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock issued as a result of the exercise of stock options.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock options exercised7falseRowperiodPeriod*RowprimaryElement*8false 4us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercisedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabelxbrli:sharesItemTypesharesNumber of share options (or share units) exercised during the current period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Stock options exercised (in Shares)duration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercisedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse118670118670falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse118670118670falsefalsefalsexbrli:sharesItemTypesharesNumber of share options (or share units) exercised during the current period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Stock options exercised (in Shares)8falseRowperiodPeriod*RowprimaryElement*9false 4us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabelxbrli:monetaryItemTypemonetaryAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 false2Costs related to stock issuanceduration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse-53000-53000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse-53000-53000falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 false2Costs related to stock issuance9falseRowperiodPeriod*RowprimaryElement*10false 4us-gaap_ProfitLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabelxbrli:monetaryItemTypemonetaryThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686 false2Net lossduration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_ProfitLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse-660000-660000falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse-660000-660000falsefalsefalsexbrli:monetaryItemTypemonetaryThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686 false2Net loss10falseRowperiodPeriod*RowprimaryElement*11false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Balance, June 30, 2013 (Unaudited)duration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse500000500000USD$falsetruefalse2truefalsefalse15170001517000USD$falsetruefalse3truefalsefalse452000452000USD$falsetruefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse4782600047826000USD$falsetruefalse7truefalsefalse-44105000-44105000USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse61900006190000USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2013-06-30T00:00:000001-01-01T00:00:002Balance, June 30, 2013 (Unaudited) at Jun. 30, 201311falseRowperiodPeriod*RowprimaryElement*12false 4us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Balance, June 30, 2013 (Unaudited) (in Shares)duration2013-01-01T00:00:002013-06-30T00:00:00 0us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse5050falsefalsefalse2truefalsefalse15501550falsefalsefalse3truefalsefalse4325141543251415falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 falseinstant2013-06-30T00:00:000001-01-01T00:00:001Balance, June 30, 2013 (Unaudited) (in Shares) at Jun. 30, 20131Derived from the audited December 31, 2012 financial statementstrueCondensed Consolidated Statements of Stockholders’ Equity (Unaudited) (USD $)NoRoundingNoRoundingUnKnownUnKnownfalsefalsefalseSheethttp://igilabs.com/role/ShareholdersEquityType2or31011 XML 14 R17.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowance, stock based compensation, provisions for sales returns, chargebacks and other allowances, and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.

Earnings Per Share, Policy [Policy Text Block]

Loss Per Share

Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Due to the net loss for the three months ended June 30, 2013 and 2012 and the six months ended June 30, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each period; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents include options and warrants to purchase the Company’s common stock and the conversion of preferred stock, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 6,049,112 for 2013 and 6,058,641 for 2012.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.

The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.

IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.

Revenue and Provision for Sales Returns and Allowances

As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.

The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.

Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.

Gross-To-Net Sales Deductions

	Three months ended June 30,				Six months ended June 30,
	2013		2012		2013		2012

Gross IGI product sales	$	2,114	$	-	$	4,380	$	-
Chargebacks		562		-		1,222		-
Sales discounts and other allowances		175		-		365		-
Gross to net adjustments	$	737		-	$	1,588		-

Net IGI product sales	$	1,377		-	$	2,792		-

Accounts receivable are presented net of SRA balances of $0.8 million and $0 at June 30, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.4 million and $0 at June 30, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.2 million and $0 for the three month periods ended June 30, 2013 and 2012, respectively, were included in cost of goods sold. Wholesale fees of $0.4 million and $0 for the six month periods ended June 30 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with the three products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.5 million and $0 at June 30, 2013 and 2012, respectively, related to these royalties. Royalty expense of $0.5 million and $0 was included in cost of goods sold for the three months ended June 30, 2013 and 2012, respectively. Royalty expense of $1 million and $0 was included in cost of goods sold for year to date as of June 30 for 2013, and 2012 respectively.

Product Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products. Sales of the IGI labeled products are recognized when received by the customer. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.

Research and Development Income: The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.

In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.

Major Customers, Policy [Policy Text Block]

Major Customers

Major customers of the Company are defined as having revenue greater than 10% of total gross revenue. For the three months ended June 30, 2013, three of the Company’s customers accounted for 41% of the Company’s revenue. For the three months ended June 30, 2012, five of the Company’s customers accounted for 74% of the Company’s revenue. Two of these customers are the same for both periods. For the six months ended June 30, 2013 and 2012, five of the Company’s customers accounted for 67% and three of the Company’s customers accounted for 64% of the Company’s revenue, respectively. Two of these customers are the same for both periods. Accounts receivable related to the Company’s major customers comprised 67% of all accounts receivable as of June 30, 2013. The loss of one or more of these customers could have a significant impact on our revenues and harm our business and results of operations.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

There were no new accounting pronouncements for the three months ended June 30, 2013 that have a material impact on the Company’s consolidated financial statements.

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References+ Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References+ Details

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Series A Preferred Stock [Member]

Convertible Preferred stock liquidation preference (in Dollars per share)

$ 500,000

^[1]

Series C Preferred Stock [Member]

Convertible Preferred stock liquidation preference (in Dollars per share)

$ 1,802,671

$ 1,764,240

^[1]

[1]	Derived from the audited December 31, 2012 financial statements

- Definition

The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.

+ References+ Details

XML 16 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

4. Inventories

Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. Inventories at June 30, 2013 and December 31, 2012 consist of:

		June 30, 2013		December 31, 2012
		(Audited)		(Unaudited)
		(amounts in thousands)
Raw materials	$	1,904	$	1,673
Work in progress		85		26
Finished goods		115		74
Total	$	2,104	$	1,773

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Note 3 - Summary of Significant Accounting Policies (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)			6,049,112	6,058,641
Accounts Payable and Accrued Liabilities	$ 0.4	$ 0	$ 0.4	$ 0
WholeSale Fees	0.2	0	0.4	0
Royalty Expense	0.5	0	1.0	0
Concentration Risk, Percentage			10.00%
Number of Customers	3	5	5	3
Percent of Revenue	41.00%	74.00%	67.00%	64.00%
Percentage of Accounts Receivable	67.00%		67.00%
Net of SRA Balance (Member)
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]
Accounts Receivable, Net	0.8	0	0.8	0
Related to Royalties (Member)
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]
Accounts Payable and Accrued Liabilities	$ 0.5	$ 0	$ 0.5	$ 0
Minimum [Member]
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]
WholeSaler, Percent of Chargebacks	90.00%		90.00%
Maximum [Member]
Note 3 - Summary of Significant Accounting Policies (Details) [Line Items]
WholeSaler, Percent of Chargebacks	95.00%		95.00%

Note 10 - Asset Purchase Agreement (Details) (USD $)	0 Months Ended
Note 10 - Asset Purchase Agreement (Details) (USD $)	Feb. 02, 2013
Asset Purchase Agreement Disclosure [Abstract]
Payments to Acquire Other Productive Assets	$ 1,400,000
Milestone Payment	$ 400,000
Finite-Lived Intangible Asset, Useful Life	15 years
No Compete Contract, Number of Years	seven

Note 5 - Stock-Based Compensation (Details) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended	132 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended			6 Months Ended	174 Months Ended		6 Months Ended	174 Months Ended
Note 5 - Stock-Based Compensation (Details) (USD $)	Apr. 12, 2010	Jun. 30, 2012	Jun. 30, 2013	Dec. 31, 2009	Dec. 31, 2012	Jun. 30, 2013 Restricted Stock [Member] 2009 Equity Incentive Plan [Member]	May 19, 2010 Restricted Stock [Member] 2009 Equity Incentive Plan [Member]	Jun. 30, 2013 Restricted Stock [Member]	Jun. 30, 2013 Restricted Stock [Member] Minimum [Member]	Jun. 30, 2013 Restricted Stock [Member] Maximum [Member]	Dec. 31, 2009 1998 Directors Stock Plan [Member]	Jun. 30, 2013 1999 Directors Stock Plan [Member]	Jun. 30, 2013 1999 Directors Stock Plan [Member]	Dec. 31, 2009 1999 Directors Stock Plan [Member]	Jun. 30, 2013 1999 Stock Incentive Plan [Member]	Jun. 30, 2013 1999 Stock Incentive Plan [Member]	May 19, 2010 2009 Equity Incentive Plan [Member]	May 19, 2010 2009 Equity Incentive Plan [Member] Maximum Number of Shares Allowed Per Year [Member]
Note 5 - Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											600,000			1,975,000	3,200,000	3,200,000	4,000,000	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			166,500										2,179,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period			72,330			230,420							(727,782)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights												one
Award Term												10 years	10 years		10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures																2,892,500
Percent FMV Common Stock Options Granted				100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period									1 year	3 years					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			2,582,000		2,606,500		1,148,748										1,858,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)			$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)			$ 904,790
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)			302,585
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)			41,654
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)			345,000					11,400
Allocated Share-based Compensation Expense (in Dollars)		$ 56,500						$ 4,900

Note 7 - License Fee (Details) (USD $)		3 Months Ended		6 Months Ended
Note 7 - License Fee (Details) (USD $)	Dec. 12, 2005	Jun. 30, 2013 Licensing Agreements [Member]	Jun. 30, 2012 Licensing Agreements [Member]	Jun. 30, 2013 Licensing Agreements [Member]	Jun. 30, 2012 Licensing Agreements [Member]
Note 7 - License Fee (Details) [Line Items]
Number of Years	10 years
Finite-Lived License Agreements, Gross	$ 1,000,000
Amortization		$ 25,000	$ 25,000	$ 50,000	$ 50,000

Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price (USD $)	6 Months Ended
	Jun. 30, 2013
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Stock Options Exercisable (in Shares)	1,034,165
Exercisable - Weighted Average Exercise Price	$ 1.17
Range $.55 - $1.00 (Member) \| Exercisable [Member]
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Range of Exercise Prices - Lower Limit	$ 0.55
Range of Exercise Prices - Upper Limit	$ 1.00
Range $.55 - $1.00 (Member)
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Stock Options Exercisable (in Shares)	212,000
Exercisable - Weighted Average Exercise Price	$ 0.75
Range $1.01 - $1.50 (Member) \| Exercisable [Member]
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Range of Exercise Prices - Lower Limit	$ 1.01
Range of Exercise Prices - Upper Limit	$ 1.50
Range $1.01 - $1.50 (Member)
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Stock Options Exercisable (in Shares)	672,165
Exercisable - Weighted Average Exercise Price	$ 1.19
Range $1.51 to $1.68 [Member] \| Exercisable [Member]
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Range of Exercise Prices - Lower Limit	$ 1.51
Range of Exercise Prices - Upper Limit	$ 1.68
Range $1.51 to $1.68 [Member]
Note 5 - Stock-Based Compensation (Details) - Exercisable Options by Exercise Price [Line Items]
Stock Options Exercisable (in Shares)	150,000
Exercisable - Weighted Average Exercise Price	$ 1.67

Note 5 - Stock-Based Compensation (Details) - Restricted Stock Awards (USD $)	Jun. 30, 2013	Dec. 31, 2012
Restricted Stock Awards [Abstract]
Non-vested balance at January 1, 2013	29,334	29,334
Non-vested balance at January 1, 2013 (in Dollars per share)	$ 1.00	$ 1.00
Non-vested balance at June 30, 2013	29,334	29,334
Non-vested balance at June 30, 2013 (in Dollars per share)	$ 1.00	$ 1.00

Note 9 - Stock Warrants (Details) - Stock Warrants Activity (USD $)	3 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Feb. 08, 2013	Dec. 08, 2010
Stock Warrants Activity [Abstract]
Beginning balance	782,259	1,235,877	427,713
Beginning balance (in Dollars per Item)	0.85	0.35	0.55	1.21
Stock warrants granted	0	0
Stock warrants granted (in Dollars per share)	$ 0	$ 0
Stock warrants expired	0	0
Stock warrants expired (in Dollars per share)	$ 0	$ 0
Stock warrants exercised	(427,713)
Stock warrants exercised (in Dollars per share)	$ 0.55
Ending balance	354,546	1,235,877	427,713
Ending balance (in Dollars per Item)	1.21	0.35	0.55	1.21

Note 5 - Stock-Based Compensation (Details) - Option Activity (USD $)	6 Months Ended
	Jun. 30, 2013
Option Activity [Abstract]
Outstanding as of January 1, 2013	2,606,500
Outstanding as of January 1, 2013 (in Dollars per share)	$ 1.10
Issued	166,500
Issued (in Dollars per share)	$ 1.12
Exercised	(118,670)
Exercised (in Dollars per share)	$ 1.08
Forfeited	(72,330)
Forfeited (in Dollars per share)	$ 1.33
Outstanding as of June 30, 2013	2,582,000
Outstanding as of June 30, 2013 (in Dollars per share)	$ 1.09
Exercisable as of June 30, 2013	1,034,165
Exercisable as of June 30, 2013 (in Dollars per share)	$ 1.17

Note 8 - Note Payable - Bank (Details) (USD $)	0 Months Ended	1 Months Ended			1 Months Ended		1 Months Ended			0 Months Ended	1 Months Ended	6 Months Ended				12 Months Ended	6 Months Ended
Note 8 - Note Payable - Bank (Details) (USD $)	Feb. 05, 2013	Feb. 28, 2013	Aug. 31, 2012	Jun. 30, 2013	Jul. 26, 2013 Subsequent Event [Member] Above Prime Rate [Member] Formula Revolving Line (Member)	Jul. 26, 2013 Subsequent Event [Member] Comany Remains in Compliance through December 2013 [Member]	Jul. 26, 2013 Subsequent Event [Member] Formula Revolving Line (Member)	Jul. 26, 2013 Subsequent Event [Member] Non-Formula Revolving Line (Member)	Jul. 26, 2013 Subsequent Event [Member] Non-Formula Revolving Line (Member) Maximum [Member]	Aug. 02, 2013 Subsequent Event [Member]	Jul. 26, 2013 Subsequent Event [Member] Maximum [Member]	Jun. 30, 2013 Above Prime Rate [Member] Formula Revolving Line (Member)	Jun. 30, 2013 Formula Revolving Line (Member) Above Prime Rate [Member]	Jun. 30, 2013 Formula Revolving Line (Member)	Jun. 30, 2013 Non-Formula Revolving Line (Member)	Dec. 31, 2012 Non-Formula Revolving Line (Member)	Jun. 30, 2013 Non-Formula Revolving Line (Member) Maximum [Member]	Jun. 30, 2013 Maximum [Member]	Jun. 30, 2013 Minimum [Member]
Note 8 - Note Payable - Bank (Details) [Line Items]
Proceeds from Lines of Credit (in Dollars)	$ 1,000,000	$ 1,000,000	$ 1,000,000							$ 1,000,000
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)			$ 3,000,000	$ 3,000,000		$ 5,000,000
Debt Instrument, Basis Spread on Variable Rate					4.90%		5.15%					1.90%	2.40%	2.15%
Line of Credit Facility, Interest Rate During Period								8.65%	8.90%						5.65%	6.15%	5.90%
Liquidity Ratio											1.00							1.25	1.00

Note 9 - Stock Warrants (Details) (USD $)	Jun. 30, 2013	Mar. 31, 2013	Feb. 08, 2013	Jun. 30, 2012	Mar. 31, 2012	Dec. 08, 2010	Dec. 12, 2005	Feb. 08, 2013 Warrants Issued in Connection with Private Placement Offering [Member]	Mar. 31, 2003 Warrants Issued in Connection with Private Placement Offering [Member]	Dec. 08, 2010 First Placement Agent [Member]	Dec. 08, 2010 Second Placement Agent [Member]
Note 9 - Stock Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	354,546	782,259	427,713	1,235,877	1,235,877				387,201	338,182	16,364
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	1.21	0.85	0.55	0.35	0.35	1.21			0.01
Number of Years							10 years	10 years
Warrants Issued, Fair Value Disclosure (in Dollars)			$ 209,000

Note 5 - Stock-Based Compensation (Details) - Options Outstanding and Exercisable (USD $)	6 Months Ended
	Jun. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in Shares)	2,582,000
Weighted Average Exercise Price	$ 1.09
Weighted Average Remaining Contractual Life	8 years 36 days
Range $.55 - $1.00 (Member)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in Shares)	218,000
Weighted Average Exercise Price	$ 0.76
Weighted Average Remaining Contractual Life	5 years 120 days
Range $.55 - $1.00 (Member) \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices - Lower Limit	$ 0.55
Range $.55 - $1.00 (Member) \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices - Upper Limit	$ 1.00
Range $1.01 - $1.50 (Member)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in Shares)	2,203,000
Weighted Average Exercise Price	$ 1.09
Weighted Average Remaining Contractual Life	8 years 146 days
Range $1.01 - $1.50 (Member) \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices - Lower Limit	$ 1.01
Range $1.01 - $1.50 (Member) \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices - Upper Limit	$ 1.50
Range $1.51 to $1.68 (Member)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in Shares)	161,000
Weighted Average Exercise Price	$ 1.67
Weighted Average Remaining Contractual Life	7 years 240 days
Range $1.51 to $1.68 (Member) \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices - Lower Limit	$ 1.51
Range $1.51 to $1.68 (Member) \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices - Upper Limit	$ 1.68

Note 6 - Income Taxes (Details)	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Equity Method Investment, Ownership Percentage	50.00%
Stockholder Ownership, Percent	5.00%

Note 1 - Organization (Details)	Jun. 30, 2013 sqft
Disclosure Text Block [Abstract]
Area of Real Estate Property	25,000

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2013	Aug. 02, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	IGI Laboratories, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		43,251,415
Amendment Flag	false
Entity Central Index Key	0000352998
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2